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IMPLANTABLE MODULAR HYDROGEL 
FOR SALIVARY GLAND RESTORATION 
2 
used for human repair. Recent work suggests that well-
defined polysaccharide gels may be a potential solution. Cell 
sourcing remains a substantial obstacle, with researchers 
reporting difficulties in reliably isolating and expanding CROSS-REFERENCE TO RELATED 
APPLICATIONS 5 human acinar, ductal, and myoepithelial cells (MECs). 
SUMMARY The present application is a continuation of PCT/US12/ 
70173, filed Dec. 17, 2012 which claims priority to U.S. 
Provisional Patent Application Ser. No. 61/576,721 filed 
Dec. 16, 2011 which is incorporated herein by reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
The present disclosure generally relates to salivary gland 
10 restoration. More particularly, the present disclosure relates 
to implantable modular hydrogels to aid in salivary gland 
restoration and associated methods. 
This invention was made with govermnent support under 
Grant No. 1R01DE022969-01 awarded by National Institute 
of Health. The govermnent has certain rights in the inven-
tion. 
In certain embodiments, the present disclosure provides a 
hydrogel network comprising: a hyaluronic acid macromer 
15 crosslinked with a multiblock copolymer. 
In certain embodiments, the present disclosure provides a 
kit comprising a hyaluronic acid macromer and a multiblock 
copolymer. 
In certain embodiments, the present disclosure provides a 
BACKGROUND 20 method of forming a hydrogel network comprising: provid-
ing a hyaluronic acid macromer; providing a multiblock 
copolymer, and crosslinking the hyaluronic acid macromer 
with the multiblock copolymer to form the hydrogel net-
Saliva is an essential oral lubricant containing an array of 
vital proteins for maintaining oral health. Head and neck 
cancers account for 3% of all malignancies in the United 
States. Dry mouth due to significant decreases in saliva 25 
secretion (xerostomia) is a permanent and devastating side 
effect of head and neck radiation that affects approximately 
40,000 patients a year in the U.S. Radiation treatment (RT) 
preferentially damages secretory acinar cells, resulting in a 
near-complete loss of saliva, a dramatic increase in tooth 30 
decay, difficulty in swallowing, and other issues. Radiation 
treatment in patients with head and neck tumors commonly 
results in hyposalivation and xerostomia due to the loss of 
fluid secreting salivary acinar cells. Patients develop sus-
ceptibility to oral infections, dental caries, impaired speech 35 
and swallowing, reducing the quality of life. 
Clinical management is largely unsatisfactory. Current 
prevention methods ( e.g. radioprotective agents or highly 
localized intensity modulated RT) are generally ineffective. 
Although advanced radiation techniques such as Intensity- 40 
Modulated Radiation Therapy (IMRT) significantly reduce 
radiation to the salivary glands compared to conventional 
radiation, a large percentage of patients develop xerostomia 
post-IMRT. Post-radiotherapy palliative therapies remain 
largely ineffective for long-term resolution of xerostomia. 45 
Other xerostomia treatments, such as artificial saliva or 
stimulatory agonists, are also largely ineffective. Tissue 
engineering offers a potential safe clinical solution for the 
regeneration of tissue and recovery of salivary function. 
Recent clinical success in tissue engineering includes 50 
tissues such as cartilage, bone and bladder. U.S. Pat. Nos. 
7,803,905 and 7,875,591, the entireties of which are hereby 
incorporated by reference, discuss methods of adhering cells 
to scaffolds and devices to induce replication of connective 
tissues. Functional reconstitution of a 3D glandular structure 55 
such as the human salivary gland is difficult, owing to a 
complex tissue structure of distinct cell types that must 
reassemble to provide vectorial secretion of a complex 
biological fluid. Despite extensive recent research in sali-
vary gland development, efforts at regeneration using the 60 
classic tissue engineering models are few, and suffer from 
insufficient sources of cells and scaffold materials. Synthetic 
scaffolds, such as PGA/PLLA lack necessary cues, have 
inappropriate mechanical properties, and produce poten-
tially inflammatory degradation byproducts. Collagen/matri- 65 
gel hybrids are closer matches to native tissue, both in gel 
modulus and composition, but murine Matrigel cannot be 
work. 
In certain embodiments, the present disclosure provides a 
method of constructing a biomimetic matrix comprising: 
providing a hyaluronic acid hydrogel network, providing 
hyaluronic acid hydrogel particles, providing salivary cells, 
and co-encapsulating the hyaluronic acid hydrogel particles 
and the salivary cells within the hyaluronic acid hydrogel 
network to form cell-laden microgel modules. 
In certain embodiments, the present disclosure provides a 
composition comprising: a hyaluronic acid macromer; a 
multiblock copolymer comprising a copolymer of PlnDIV 
peptide alternating with PEG; and hyaluronic acid hydrogel 
particles. 
The features and advantages of the present disclosure will 
be apparent to those skilled in the art. While numerous 
changes may be made by those skilled in the art, such 
changes are within the spirit of the invention. 
DRAWINGS 
The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawings will be provided by the 
office upon request and payment of the necessary fee. 
Some specific example embodiments of the disclosure 
may be understood by referring, in part, to the following 
description and the accompanying drawings. 
FIG. 1 is drawing that illustrates a strategy for creating 
salivary cell modules. Strategy for creating salivary cell 
modules. GP-loaded HGPs will be co-encapsulated within 
an HA matrix, crosslinked by a PlnDIV-PEG copolymer to 
produce microscale Cell-MMs. Multiple Cell-MMs will 
then be gelled with angiogenic HGPs to produce a 3D-ST 
implant. 
FIG. 2 is a drawing that illustrates a research strategy for 
Cell-MM formation. Cell-MM formation allows many ver-
satile combinations of materials and cells to be included. 
Salivary cells will be cultured in HA hydrogels, with GF-
loaded HGPs to enhance cell growth and progenitor char-
acter, optimize lumen formation via [PlnDIV-PEG], induce 
acinus extension and/or branching via FGF7/10 gradients 
and stabilize structures via MEC support. 
FIG. 3 is a drawing that illustrates a strategy for design 
and in vivo testing of various 3D-ST composite constructs. 
US 9,642,941 B2 
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HGPs and MMs can be encapsulated in HA to assess the 
following points: using VEGF/FGF2 HGPs alone in HA to 
optimize angiogenesis, adding cell-free MMs to confirm 
neovessel access to MMs, confirming acinar-enriched cell 
assembly in cell-MMs in vivo and determining the need for 5 
MECs in fully-assembled 3D-STs. 
FIG. 4 illustrates HGP images. (a) Scanning electron 
micrograph (SEM) of 10 µm HGPs; (b) diagram of HBGF 
binding to PlnDI(HS) or heparin throughout the porous HGP 
(c) cryogenic SEM image of HA DXN 10 
FIG. 5 is a drawing that illustrates multiblock [PlnDIV-
PEG]n copolymer crosslinkers. Multiblock [PlnDIV-PEG]n 
copolymer crosslinkers [PlnDIV-PEG]n are synthesized by 
step growth polymerization via orthogonal CuAAC click 15 
chemistry 
FIG. 6 is a schematic of HA carrying unsaturated double 
bonds (HA-AC). n=0-3. 
FIG. 7 is a chart depicting the relationship between 
cumulative release and time. GF release kinetics from 20 
HGPs, functionalized with low (HP!) or high (HPlO, 
HP! 00) levels of heparin. GF release can be tuned to vary 
inversely with HP content. 
4 
spikes in spheroids in response to ACh treatment, observed 
by Fluo-4 imaging. (g) confocal line scan intensity; (h) 
sample image. 
FIG. 17 illustrates the biocompatibility of HA hydrogels 
in nude rat. Bare HA hydrogel after (a) 11 d, (b) 4 w of 
implantation. (c.d) Cell-loaded implants maintain cells in 
spheroids (boxed) in vivo in the back ( c) and parotid bed ( d). 
Cells express ~-amylase (red) and cytokeratins (green). HA 
hydrogels with empty HGPs ( e) and VEGF-loaded HGPs (f) 
after 1 w in parotid bed. The intense red color (f) is due to 
increased vascularization over control (e). 
FIG. 18 shows Acini-like spheroids in 3D HA hydrogels. 
Spheroid structures express tight junction markers CL-1 (A), 
Z0-1 (B), E-cadherin (D) and adherens junction marker, 
~-catenin (C). Live/Dead staining shows Syto13 positive 
green cells and propidium iodide positive red cells (E). A 
representative phase image of an acinus-like structure is 
seen in F. Nuclei stain blue. An illustration of hydrogel 
dimensionality is seen in G. 
FIG. 19 shows (A) Differences in growth of acini-like 
structures in 2.5D (red) and 3D (blue) HA hydrogels. (B) 
Quantification of dsDNA in acini-like structures growing in 
3D HA hydro gels. Each point represents the average of n=3 
measurements. Error bars are +/- standard error. ( C) and (D) 
show Ki67 staining (green) in acini-like structures at day 26 
(C) and at day 48 (D). 
FIG. 20 shows salivary acinar-like cell assemblies express 
receptors for neurotransmitters. Confocal images show 
expression of ~1 adrenergic receptor (A, D, G, J), 2 adren-
FIG. 8 is a drawing that illustrates a method for making 
cell-MMS. Microfabrication method to make cell-MMs. (a) 25 
Laser-cut patterns in PDMS with varying xy features; (b) 
SEM of 1 mm well in a PDMS template; (c) multiple HA 
hydrogel discs from circular templates; (d) 3D confocal 
image of bilayers in (c), using covalently-bound fluors. 
Scale bar=4 mm 30 ergic receptor (B, E, H, K), and M3 muscarinic receptor (C, 
F, I, L) in 2D cultured cells (A-C), on 2.5D HA hydrogels 
(D-F), in 3D hydrogels (G-I) and in tissue (J-L). Nuclei stain 
red. 
FIG. 9 is a picture that illustrates human salivary-derived 
cells in 2D culture. (a,b) acinar cells, >99% CK5+ and 
~-amylase+; (c) co-culture of ductal cells (CK19+, red) and 
acinar cells; (d) myoepithelial cells (MECs). 
FIG. 10 is a picture that illustrates human acinar cells in 35 
3D culture in HA hydrogels. (a-b) Stained for ~-catenin 
(green), showing merging structures in (b ); ( c) reconstructed 
confocal microscopy images featuring nuclei (blue), 
SYT013 (green), and propidium iodide (red). Images dem-
onstrate extended cultures with large acinar structures at day 40 
20 and 40. 
FIG. 11 is a picture that depicts the expression of pro-
genitor markers in 3D HA cultures. (a) CK5 expression 
throughout mature spheroids, co-stained for ~-catenin at 
cell-cell junctions; (b,c) Msi-1 expressed throughout spher- 45 
oid cell aggregates, with c-Kit visible at peripheries. 
FIG. 12 is a picture depicting organized spheroids on 
PlnDIV-HAgels. at early timepoints. Note lumen formation 
in lower right image. 
FIG. 21 shows salivary acinar-like cell assemblies in 2.5D 
and 3D HA hydrogels form secretory granules upon treat-
ment with isoproterenol (ISO) and norepinephrine (NER). 
Images captured with the confocal microscope using bright-
field and fluorescence. Panels A-C show cells on 2.5D 
hydrogels while panels D-F show cells encapsulated in 3D 
hydrogels. Control untreated cells are shown in panels A and 
D. Cells treated with 50 µM ISO for 60 minutes (B, E) show 
presence of granules (arrows). Cells treated with 50 µM 
NER for 60 minutes (C, F) also show granule production. 
a-Amylase is stained red. 
FIG. 22 demonstrates the distance of a-amylase release 
from each acini, as measured from fluorescence staining for 
a-amylase. As seen in the measurements, acini are respon-
sive to ISO and NER, since these two agents induce a further 
distance of a-amylase release. a-amylase production is 
FIG. 13 is a drawing that illustrates method for varying 
PlnDIV global and local levels. 
50 visible as a halo surrounding the cells in 3D culture. 
FIG. 14 is a picture depicting organized spheroids. FGF7 
treatment increases spheroid size in 3D HA hydrogels. (a) 
Untreated cells at 20 d culture. (b,c) Spheroids treated with 
25 ng/mL FGF7 daily for (b) 10 d and ( c) 12 d. 55 
FIG. 15 is a picture depicting Z0-1 staining. Z0-1 
staining (red) in breast (a-b, from, demonstrating (a) "inside-
out" acini polarity, and (b) correct stable polarity induced by 
MEC contact; ( c) 3D acinar spheroid culture on our HA 
hydrogels, showing a mixture of peripheral (i.e. inverted) 60 
Z0-1 expression, and correct luminal expression of Mucl. 
FIG. 16 illustrates the response of spheroids in HA to 
neurotransmitters. (a-c) Expression of adrenergic/muscar-
inic receptors in spheroids; (d-f) Spheroid response to iso-
proterenol or norepinephrine, demonstrating peripheral 65 
granule formation and concentrated ~-amylase over 
untreated control (d); Arrows point to granules; (g-h) Ca2+ 
FIG. 23 is a complementary measure of a-amylase 
response, using an integrated intensity of the antibody 
fluorescence over a selected area to demonstrate a-amylase 
release in response to ISO and NER agents. 
FIG. 24 shows and establishes the area of identified 
a-amylase response around each cell assembly. The increase 
in area for ISO and NER-treated assemblies confirms their 
responsiveness to these two agents. 
FIG. 25 shows amylase production for cells treated with 
ISO. a-Amylase is stained red. The outlined region of 
interest was used for quantification of a-amylase response. 
FIG. 26 shows the number of secretory granules of cell 
assemblies after treatment with isoproterenol (ISO) and 
norepinephrine (NER) as compared to controls. 
FIG. 27 illustrates that acetylcholine induces intracellular 
calcium release in self-assembling acini-like structures cul-
tured on HA hydrogels. Intracellular calcium is released 
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from the ER stores upon activation of M3 muscanmc 
receptors. Calcium curves generated from cells on 2.5D 
hydrogels (A), and oscillations from cells in 3D hydrogels 
(D), upon treatment with 50 µM acetylcholine. Calcium 
oscillations generated upon treatment with 100 M acetyl-
choline in cells in 2.5D (B) and in 3D (E). Red arrow 
indicates the time-point at which acetylcholine was added. 
Representative images of structures in 2.5D (C) and in 3D 
6 
membranes via transcellular transport or through the tight 
junctional barrier via paracellular transport. Studies with rat 
and rabbit submandibular glands showed that most fluid is 
transported via the paracellular pathway with less trans-
5 ported via the transcellular pathway. The transepithelial 
movement of water via the paracellular pathway is the 
primary mechanism for fluid secretion by salivary acinar 
cells. 
(F) responding to acetylcholine are seen in a rainbow/heat 
map scale where red indicates the highest response and blue 10 
indicates the lowest or no response. 
Fluid secretion can be activated by binding of acetylcho-
line to M3 muscarinic receptors, and subsequent activation 
of G proteins. The a-component of the G protein then 
dissociates and activates phospholipase C (PLC), forming 
inositol triphosphate (IP 3 ) and releasing calcium from intra-
cellular stores. Calcium then activates the apical calcium 
FIG. 28 shows survival and retention of acini-like struc-
tures in 2.5D and 3D hydrogels. 2.5D implants wrapped in 
gelatin membranes removed from athymic rats at day 11 (A) 
and at 3 weeks (B). 3D implants removed from athymic rats 15 
at day 11 (D) and at 3 weeks (E). Dispersed single cells 
positive for a-amylase (red) in rat tissue stained with 
vimentin (green) are seen in panel C. Intact spheroid struc-
tures (boxed) in the 3D hydrogel implant stained for a-amy-
lase (red) and ~-catenin (green) are seen in panel F. Arrows 20 
point to blood vessels. 
activated chloride charmels. As chloride is released into the 
lumen, sodium from the interstitium follows. The resulting 
sodium chloride creates an osmotic gradient that drives 
transepithelial movement of water into the lumen. 
The present disclosure describes an implantable, biologi-
cally-based cell-seeded 3D implant that will aid in restoring 
salivary function in patients suffering from xerostomia. 
The present disclosure also describes a novel modular 
approach for the creation of functional salivary cell hydrogel 
assemblies (cell-MMs) that can be co-assembled into a 
larger 3D-ST (3D salivary neotissue) hydrogel for direct 
implantation into patients. FIG. 1 illustrates such an 
approach. Specifically, biomimetic matrices providing 
defined biological cues can be constructed from these build-
ing blocks: (1) chemically modified hyaluronic acid (HA) 
While the present disclosure is susceptible to various 
modifications and alternative forms, specific example 
embodiments have been shown in the figures and are herein 
described in more detail. It should be understood, however, 25 
that the description of specific example embodiments is not 
intended to limit the invention to the particular forms 
disclosed, but on the contrary, this disclosure is to cover all 
modifications and equivalents as illustrated, in part, by the 
appended claims. 30 with reactive handles; (2) multiblock copolymer cross-
linkers, and (3) microscale densely crosslinked HA-based 
hydrogel particles (HGPs ), which serve as depots for growth 
factors (GF). HGPs (pre-loaded with selected GFs) and 
salivary cells may be co-encapsulated within an HA hydro-
DESCRIPTION 
The present disclosure generally relates to salivary gland 
restoration. More particularly, the present disclosure relates 
to implantable modular hydrogels for salivary gland resto-
ration and associated methods. 
Salivary tissue engineering potentially offers permanent 
relief of xerostomia. The autonomic nervous system inner-
vates salivary acinar, myoepithelial, vascular and interca-
lated duct cells. Salivary acinar cells secrete most of the 
fluid, electrolyte and proteins in saliva. Neurotransmitter 
receptors are present on the basolateral membranes of acinar 
cells that possess a-adrenergic, ~-adrenergic, M3 muscar-
inic, and cholinergic substance P receptors.3 The major 
pathway for protein exocytosis occurs via activation of 
~-adrenergic receptors (sympathetic pathway), while the 
primary stimulation for fluid secretion occurs through acti-
vation of the M3 muscarinic receptors (parasympathetic 
pathway). 
The most abundant protein in saliva, a-amylase, com-
prises 10% of all salivary protein and is actively secreted by 
stimulated acinar cells. Secreted salivary proteins such as 
a-amylase are stored at high concentrations in specialized 
secretory granules. Two distinct pathways regulate traffick-
ing of secreted and ECM proteins. Several are secreted by a 
constitutive pathway that allows for exocytosis of secreted 
proteins without stimulation. However, exocytosis can be 
regulated for controlled release of granule contents. The 
regulated secretory pathway is the major pathway for gran-
ule exocytosis. In this pathway, neurotransmitter agonists 
such as norepinephrine bind to G-protein coupled ~-adren-
ergic receptors that, in turn, activate the adenyl cyclase/ 
cAMP/Protein Kinase A (PKA) second messenger pathway 
to stimulate protein exocytosis. 
Transport of fluid also occurs in two distinct ways among 
glandular epithelia. Fluid can move through the plasma 
35 gel network to form cell-laden microgel modules (cell-MM). 
Cell-MMs may be the primary modular building blocks for 
this device. Additional complexity may be built by gelling 
multiple cell-MMs into a secondary HA network, yielding a 
larger, macroscopic 3D-ST construct for final implantation. 
40 The modular building blocks, when combined with the 
salivary cellular components, may create a new solution for 
patients suffering from xerostomia. 
In one embodiment, the present disclosure provides for a 
hydrogel network comprising: a hyaluronic acid (HA) mac-
45 romer crosslinked with a multiblock copolymer. HA is a 
naturally-derived, biocompatible matrix that can be chemi-
cally functionalized for use as a crosslinkable tissue engi-
neering scaffold. Unlike other hydrogels, HA is uniquely 
recognized by cellular receptors, in particular CD44, 
50 ICAM-1 and RHAMM. HA is a ubiquitous polysaccharide 
found throughout the ECM, and unlike poly(ethylene gly-
col) (PEG) and other hydrogels, it binds specific receptors 
(CD44, RHAMM, ICAM-1), which are expressed on sali-
vary gland cells, and direct multiple cell functions including 
55 adhesion, migration, and morphogenesis. HA derivatives 
with reactive handles can be used for in situ cell encapsu-
lation for 3D culture purposes. The HA may be functional-
ized with any group that would allow for it to be crosslinked 
with a multiblock copolymer. In certain embodiments, the 
60 HA may be functionalized with an unsaturated double bond 
(FIG. 6). In certain embodiments, the HA may be function-
alized with an acrylate group. The hydrogel network of the 
present disclosure may be biocompatible. 
The multi-block copolymer of the present disclosure may 
65 comprise an alternating copolymer of PEG and a peptide 
epitope of perlecan. Cell-instructive biological cues may be 
incorporated into the HA networks using the novel multi-
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block alternating copolymer of PEG and a peptide epitope be any cells or combinations of cells derived from the 
from perlecan. Perlecan (Pin) is a proteoglycan present in all salivary gland, including but not limited to stromal, epithe-
basement membranes where it serves as both a structural lial, myoepithelial, ductal, and nerve cells. In certain 
boundary marker and as a reservoir for heparan sulfate/ embodiments, the cells may be salivary cells. In certain 
heparin (HS/HP) binding growth factors (HBGFs). Pin 5 embodiments, the cells may be parotid gland derived cells. 
offers a novel alternative for tissue engineering applications In certain embodiments, the cells may be salivary gland 
compared to other biologicals (e.g. collagen, fibronectin, progenitor cells. In certain embodiments, the cells may be 
laminin, Matrigel). In certain embodiments, two specific salivary acinar-like cells. In certain embodiments, the cells 
segments of Pin may be employed: (a) Domain I of Pin may be included in the hydrogel network in an amount 
(PlnDI) includes three polysaccharide chains of predomi- 10 ranging from about lxl05 cells/200 µL volume ofhydrogel 
nantly heparan sulfate, which bind HBGFs in native tissue, to about lxl07 cells/200 µL volume of hydrogel. The 
and which will be used here (as a depot for delivery of amount of cells included in the hydrogel network will 
multiple relevant GFs; (b) Within Pin Domain IV, a 17-mer depend on the specific cell type and desired application. In 
sequence (PlnDIV peptide) interacts preferentially with epi- certain embodiments, the cells may be treated with ~-adren-
thelial cells, which may be used to influence salivary cell 15 ergic agonists. In certain embodiments, the cells may be 
organization. U.S. Pat. No. 7,875,591 describes delivery treated with M3 muscarinic agonists. In certain embodi-
systems for heparin-binding growth factors, the disclosure ments, the cells may be treated with norepinephrine, iso-
of which is herein incorporated by reference. proterenol, acetylcholine, and combinations thereof. In cer-
In certain embodiments, PlnDIV peptide may be used in tain embodiments, ~-adrenergic agonists, M3 muscarinic 
the multiblock PEG copolymers described above. U.S. Pat. 20 agonists, norepinephrine, isoproterenol, and acetylcholine 
No. 7,803,905 describes the perlecan domain IV peptide, the may be delivered to cells using HA-based hydrogel par-
disclosure of which is herein incorporated by reference. In ticles. 
certain embodiments, [PlnDIV-PEG]n copolymers may pro- In certain embodiments, HA-based hydrogel particles 
vide additional cellular cues in the HA matrix, amplified (HGP) may also be included in the hydrogel network. In 
through multivalency to elicit coordinated and dynamic 25 certain embodiments, HGPs may be included in the hydro-
cell-matrix interactions. Michael-type addition reactions gel network in an amount of from about lxl04 to lxl06 
may be employed between sulfhydryl groups on the [Pin- HGPs per hydrogel network, however the amount of HGPs 
DIV-PEG]n copolymer and reactive double bonds on HA to can be tailored depending on the specific application. In 
form the secondary network. This reaction occurs rapidly at certain embodiments, HGPs may provide local growth fac-
pH 7, resulting in a thioether bond with no toxic byproducts. 30 tor stores to induce progranimed morphogenesis. The HGPs 
Hydrogel stability can be tuned by varying the neighboring can be tailored to provide various amounts of growth factor 
groups to the thioether. depending on the application. In certain embodiments, the 
In certain embodiments, [PlnDIV-PEG]n multiblock HGPs may be angiogenic HGPs. In certain embodiments, 
copolymers may be synthesized via condensation polymer- HGPs of micro- to nano-dimensions may be embedded 
ization using copper(I)-catalyzed alkyne-azide cycloaddi- 35 within porous HA hydrogel matrices (FIG. 4). In certain 
tion reaction (CuAAC). Azide-terminated, telechelic PEG embodiments, the HGPs may be spherical. In certain 
with Mn of 400, 1,450, 3,400 and 5,000 may be synthesized embodiments, the spheres may have a diameter in the range 
and purified. PlnDIV peptide may be tagged with the non- of from about 500 nm to about 10 µm. HGPs may be 
natural amino acid, propargyl glycine, to facilitate CuAAC chemically functionalized to crosslink with both the HA 
coupling between peptide and a,w-azido PEG. The func- 40 hydrogel matrix, and with other HGPs, enabling tailored 
tional group tolerance of CuAAC and the modular nature of viscoelasticity, enzymatic stability and structural integrity, 
the synthesis permit ready adjustment of the composition of essential for tissue regeneration. These properties can be 
the multiblock. easily tuned by varying the size and number of HGPs, the 
In certain embodiments, the multiblock copolymer com- crosslinking chemistry, and the density of the primary and 
prises a multiblock alternating copolymer of poly(acrylic 45 the secondary networks. HGPs may also deliver and release 
acid) (PAA) and a hydrophobic peptide with a sequence of therapeutic GFs at targeted locations and controlled rates 
(VPGVG)2 . In certain embodiments, a combination of mu!- (FIG. 7) to elicit desired cellular behavior. In certain 
tiblock copolymers may be used in the hydrogel network. embodiments, HGPs may be co-encapsulated, and may 
For example, in certain embodiments, a combination of a release HBGFs sequentially in a controlled manner to induce 
multiblock copolymers comprising a multiblock alternating 50 cellular differentiation and tissue morphogenesis in situ. The 
copolymer of poly(acrylic acid) (PAA) and a hydrophobic modular nature of the building blocks allows for fine-tuning 
peptide with a sequence of (VPGVG)2 may be combined of the biological and biomechanical properties of the result-
with a multiblock copolymer [PlnDIV-PEGJn. ing matrix. 
In certain embodiments, to render the multiblock capo- Salivary gland morphogenesis and angiogenesis require 
lymers crosslinkable towards HA derivatives carrying an 55 coordination among multiple GFs, including HB-EGF, 
unsaturated double bond (FIG. 6), a cysteine residue may be FGF2, FGF7, FGFlO and VEGF. The hydrogel network of 
added to the basic peptide sequence. The peptide motifs may the present disclosure may comprise local GF stores capable 
be X(PlnDIV)XGGC, where PlnDIV will have a sequence of controlled delivery. For example, covalently immobilized 
ofTWSKVGGHLRPGIVQSG, Xis propargyl glycine, G is PlnDI(HS) or heparin (HP) on HGPs may be used for the 
a gly spacer and C is a cys tag. Peptides may be prepared by 60 non-covalent association of the HBGFs, allowing HBGFs to 
solid phase peptide synthesis and purified. The [PlnDIV- form latent complexes through their specific binding. Such 
PEGJn products may be purified and characterized by stan- strategies offer the potential for sustained release over 
dard means. Filtration through Cuprisorb resin and dialysis timescales relevant to controlling the initial cellular assem-
against thiourea, imidazole, NaCl, and pure water solutions bly in vitro and subsequent angiogenesis of the neotissue in 
may yield polymers that are non-toxic to cells. 65 vivo. It has been shown that HGPs, covalently functional-
In certain embodiments, cells may be encapsulated within ized with PlnDI(HS), can sequester BMP-2, modulate its 
the hydrogel network. In certain embodiments, the cells may release, and potentiate its biological functions, both in vitro 
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and in vivo. Similar sustained release of BMP-2 may be 
achieved using HGPs with covalently integrated HP (see 
FIG. 7). 
10 
acid hydrogel particles and the cells within the hyaluronic 
acid hydrogel network to form cell-laden microgel modules. 
In certain embodiments, the method may further comprise 
gelling multiple cell-laden microgel modules into a second-Covalently immobilized PlnDI(HS) or HP may be used 
for non-covalent GF association. Sequential GF release may s ary hyaluronic acid network to yield macroscopic 3D-ST. 
In certain embodiments, the present disclosure provides a 
kit comprising a hyaluronic acid macromer and a multiblock 
copolymer. 
To facilitate a better understanding of the present disclo-
10 sure, the following examples of certain aspects of some 
embodiments are given. In no way should the following 
examples be read to limit, or define, the entire scope of the 
disclosure. 
be achieved by tailoring GF affinity for HGPs via the 
variation of HS/HP content in the particles. When HS/HP 
content is high, GF release is slow, as locally dissociated 
proteins are rapidly recaptured by unoccupied HS/HP sites 
before they can diffuse into the surrounding medium. When 
HS/HP content is low, GF is rapidly released through 
diffusion. It has been demonstrated that controlled BMP-2 
release by HA/HP hybrid particles, along with the innate 
bioactivity of HA, induced robust and consistent chondro-
genic differentiation of mesenchymal stem cells. The rela- 15 
tive amount of HP incorporated in HGPs may be easily 
tuned by varying the HA/HP ratio in feed during particle 
synthesis. 
In certain embodiments, multiple hydrogel networks can 
be co-assembled to form a secondary hydrogel network. The 20 
secondary network may be a larger 3D assembly or construct 
that may be implanted into a subject. In certain embodi-
ments, the secondary network may be formed by coassem-
bly individual hydrogel networks with hyaluronic acid and 
HA hydrogel particles. In certain embodiments, the HA 25 
hydrogel particles may comprise angiogenic HGPs. 
EXAMPLES 
Example 1 
Materials and Methods: An IRB approved tissue collec-
tion protocol was established and salivary tissue was 
obtained from patients undergoing surgery. Tissue speci-
mens were dissociated to obtain cultures of human salivary 
acinar progenitor cells. In order to mimic the native glan-
dular tissue, a biocompatible and biodegradable hyaluronic 
acid (HA) based HYSTEM™ hydrogel system (Glycosan 
Biosystems, Salt Lake City, Utah) was utilized to encapsu-
late cells in 3D. Encapsulated salivary acinar progenitor 
cells rapidly formed 3D spheroid structures with lumen and 
retained typical salivary biomarkers. The spheroid structures 
demonstrated functionality by responding to stimulation by 
neurotransmitter agonists that activated their protein and 
fluid production pathways. 
Results: In order to investigate the long-term survival and 
structure retention of salivary gland spheroids in vivo, these 
Under this autologous restoration paradigm, the salivary 
gland progenitor cells may be isolated prior to radiation 
treatment, expanded and/or manipulated in vitro, and 
returned to the site of injury via a biocompatible implant. 30 
Salivary gland regeneration is particularly challenging, as 
the gland is a complex physiological system, and requires 
multiple cell types, which will necessitate a modular system 
with flexible control over physical properties and display of 
appropriate biological signals. 35 cell-seeded HA hydrogels were implanted in an animal 
model. Immunocompromised hooded athymic rats were 
used to avoid rejection of human salivary cells by the rat 
immune system. HA hydrogels containing salivary spher-
FIGS. 1 and 2 illustrate the steps involved for forming an 
implantable module hydrogel to aid in salivary gland res-
toration. An alternative embodiment is illustrated in FIG. 3. 
Although the model described above may be specific for 
autologous transplantation, if may be combined with tissue 40 
typing and be useful for allografting as well. One concern 
with this approach would be the rejection of the implant. 
In certain embodiments, the hydrogel networks of the 
present disclosure may be used to treat a subject suffering 
from xerostomia. In certain embodiments, the hydrogel 45 
networks of the present disclosure may be used to aid in 
salivary gland restoration. 
In certain embodiments, the present disclosure provides a 
method of forming a hydrogel network comprising: provid-
ing a hyaluronic acid macromer; providing a multiblock so 
copolymer, and crosslinking the hyaluronic acid macromer 
with the multiblock copolymer to form the hydrogel net-
work. In certain embodiments, the multiblock copolymer 
comprises a multiblock copolymer of PlnDIV peptide alter-
nating with PEG. In certain embodiments, the multiblock 55 
copolymer comprises a multiblock copolymer of poly 
(acrylic acid) (PAA) alternating with a hydrophobic peptide 
of sequence of (VPGVG)2 . In certain embodiments, the 
method may further comprise providing hyaluronic acid 
hydrogel particles. In certain embodiments, the hyaluronic 60 
acid hydro gel particles may comprise a growth factor and be 
capable of controlled release and delivery of growth factors. 
In certain embodiments, the present disclosure provides a 
method of constructing a biomimetic matrix comprising: 
providing a hyaluronic acid hydrogel network, providing 65 
microscale densely crosslinked hyaluronic acid hydrogel 
particles, providing cells, co-encapsulating the hyaluronic 
oids were implanted subcutaneously in the backflaps of nude 
rats. The implanted HA hydrogels maintained biocompat-
ibility with the host and degraded significantly by four 
weeks. Encapsulated cells maintained viability for over 
three weeks and retained salivary biomarkers such as 
a-amylase, cytokeratins, and junctional proteins in vivo. 
Encapsulated salivary cells also maintained their spherical 
luminal structure throughout this time. In order to surgically 
simulate acinar cell loss, a parotid gland resection model 
was developed in which 314 of the left parotid gland of a nude 
rat is resected. The right parotid is left intact so that there is 
minimal detriment to the animal from the reduction in saliva 
and also acts as a control. Acellular HA hydrogels in the 
parotid bed showed vascularization by the host at the 
one-week time point. Cell-seeded hydrogels, in the 314 resec-
tion model, maintained viability of the encapsulated spher-
oids and expression of their phenotypic biomarkers in vivo. 
In an effort to increase angiogenesis into the implant, HA 
hydrogels were engineered to include VEGF loaded HA 
particles. Preliminary studies with acellular HA hydrogels 
containing VEGF loaded HA particles, implanted in the 314 
resected parotid bed, showed a robust increase in angiogen-
esis in one week. Future studies will involve long-term 
implantation of cell-seeded HA hydrogels with VEGF 
loaded particles in the parotid resection rat model, to assess 
the functionality of these engineered gels in vivo. 
Conclusion: A hydrogel culture system capable of sup-
porting 3D salivary spheroid structures in vivo was estab-
lished. The hydrogel culture system reported here will aid 
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the development of an artificial salivary gland that can be 
used to relieve symptoms of patients suffering from xero-
stomia. 
Example 2 
HA-based, doubly crosslinked networks (DXNs) have 
been developed that are hierarchically structured, mechani-
cally robust and biologically active. In these systems, HGP 
spheres of micro- to nano-dimensions are embedded within 
porous HA hydrogel matrices (as shown in FIG. 4). HGPs 
are chemically functionalized to crosslink with both the HA 
hydrogel matrix, and with other HGPs, enabling tailored 
viscoelasticity, enzymatic stability and structural integrity, 
essential for tissue regeneration. These properties can be 
easily tuned by varying the size and number of HGPs, the 
crosslinking chemistry, and the density of the primary and 
the secondary networks. HGPs also deliver and release 
therapeutic GFs at targeted locations and controlled rates (as 
shown by FIG. 7) to elicit desired cellular behavior. Salivary 
gland-specific materials based on HA DXNs may employ 
dynamic biological and mechanical features to promote and 
control morphogenesis. 
Separately, hybrid alternating copolymers that mimic the 
chemical, structural, and mechanical properties of natural 
ECM proteins have been created. Mimetic hybrid copoly-
mers containing PEG alternating with the alanine-rich, 
lysine-containing peptide (AKAAAKA)2 were synthesized 
and tagged with a fibronectin-derived RGD peptide. The 
resultant multiblock copolymers, when covalently cross-
linked, have mechanical properties similar to natural elastin 
and are capable of supporting the attachment and prolifera-
tion of fibroblasts. Similar hybrid multiblock alternating 
copolymers of poly(acrylic acid) (PAA) and a hydrophobic 
(VPGVG)2 (vG2) peptide from natural elastin self-assemble 
into stable, pH-responsive nanoparticles in aqueous solu-
tion. These soft, hybrid materials can incorporate specific 
epitopes to make them attractive materials for salivary gland 
tissue engineering. 
HA plays critical roles in cell signaling, embryonic devel-
opment and tissue morphogenesis, underscoring its potential 
12 
ethyl acrylate oligomers (NHS-[2CEJnAC) in HEPES buffer 
at pH 7.2. Varying reaction stoichiometry will vary the% 
acrylate incorporation. The hydrolysis rate of the thiol-
acrylate adduct may be adjusted by altering the number of 
5 ester repeats in NHS-2-[CEJnAC. The product may be 
purified and characterized by standard means prior to use. 
[PlnDIV-PEG]n multiblock crosslinkers may be synthe-
sized via condensation polymerization using copper(I)-cata-
lyzed alkyne-azide cycloaddition reaction (CuAAC). Azide-
10 terminated, telechelic PEG with Mn of 400, 1,450, 3,400 and 
5,000 may be synthesized and purified. PlnDIV peptide may 
be tagged with the non-natural amino acid, propargyl gly-
cine, to facilitate CuAAC coupling between peptide and 
a,w-azido PEG. The functional group tolerance of CuAAC 
15 and the modular nature of the synthesis permit ready adjust-
ment of the composition of the multiblock. To render the 
multiblock copolymers crosslinkable towards HA-AC, a 
cysteine residue may be added to the basic peptide sequence. 
The peptide motifs may be X(PlnDIV)XGGC, where Pln-
20 DIV will have a sequence ofTWSKVGGHLRPGIVQSG, X 
is propargyl glycine, G is a gly spacer and C is a cys tag. 
Peptides may be prepared by solid phase peptide synthesis 
and purified. The [PlnDIV-PEG]n products may be purified 
and characterized by standard means. Filtration through 
25 Cuprisorb resin and dialysis against thiourea, imidazole, 
NaCl, and pure water solutions may yield polymers that are 
non-toxic to cells. 
Salivary gland morphogenesis and angiogenesis require 
precise coordination among multiple GFs, including HB-
30 EGF, FGF2, FGF7, FGFlO and VEGF. The proposed bio-
active HA matrices will contain local GF stores capable of 
controlled delivery. Covalently immobilized PlnDI(HS) or 
heparin (HP) on HGPs may be used for the non-covalent 
association of the HBGFs, allowing HBGFs to form latent 
35 complexes through their specific binding. Such strategies 
offer the potential for sustained release over timescales 
relevant to controlling the initial cellular assembly in vitro 
and subsequent angiogenesis of the neotissue in vivo. It has 
been shown that HGPs, covalently functionalized with Pln-
40 DI(HS), can sequester BMP-2, modulate its release, and 
potentiate its biological functions, both in vitro and in vivo. 
Similar sustained release of BMP-2 may be achieved using 
HGPs with covalently integrated HP (see FIG. 7). HGPs 
with 0.55 µg HP/mg HGPs (HA-HP!), may release both 
as an instructive hydrogel matrix for salivary gland tissue 
engineering. HA DXNs may be constructed from modular 
building blocks at both the molecular and microscopic 
levels. The hydro gel network may be formed by crosslinking 
HA macromers with a multiblock copolymer of PlnDIV 
peptide alternating with PEG. These [PlnDIV-PEG]n copo-
lymers may provide additional cellular cues in the HA 
matrix, amplified through multivalency to elicit coordinated 
and dynamic cell-matrix interactions. Michael-type addition 
reactions may be employed between sulfhydryl groups on 
the [PlnDIV-PEGJn copolymer and reactive double bonds on 
HA to form the secondary network. This reaction occurs 
rapidly at pH 7, resulting in a thioether bond with no toxic 
byproducts. Hydrogel stability can be tuned by varying the 
neighboring groups to the thioether. Within this matrix, 
HGPs may be co-encapsulated, and may release HBGFs 
sequentially in a controlled manner to induce cellular dif-
ferentiation and tissue morphogenesis in situ. The modular 
nature of the building blocks allows for fine-tuning of the 60 
biological and biomechanical properties of the resulting 
45 VEGF and FGF-7 in a controlled manner, with faster VEGF 
release than FGF7. This is not surprising given the higher 
dissociation constant (Kd) for VEGF /HP (165 nM) complex 
than for FGF7/HP (30-49 nM). 
Covalently immobilized PlnDI(HS) or HP may be used 
50 for non-covalent GF association. Sequential GF release may 
be achieved by tailoring GF affinity for HGPs via the 
variation of HS/HP content in the particles. When HS/HP 
content is high, GF release is slow, as locally dissociated 
proteins are rapidly recaptured by unoccupied HS/HP sites 
55 before they can diffuse into the surrounding medium. When 
HS/HP content is low, GF is rapidly released through 
diffusion. It has been demonstrated that controlled BMP-2 
release by HA/HP hybrid particles, along with the innate 
bioactivity of HA, induced robust and consistent chondro-
genic differentiation of mesenchymal stem cells. The rela-
tive amount of HP incorporated in HGPs may be easily 
matrix. 
HA derivatives carrying unsaturated double bonds (HA-
AC, as shown in FIG. 6) may be prepared by reacting adipic 
acid dihydrazide (ADH)-modified HA (routinely synthe-
sized in the Jia Group with a degree of modification of 
32-37%) with N-hydroxysuccinimide-activated 2-carboxy-
tuned by varying the HA/HP ratio in feed during particle 
synthesis, but modulation of PlnDI(HS) content may require 
multiple steps. Recombinant PlnDI(HS) with a C-terminal 
65 cysteine (5 residues into domain II) may be generated in the 
lab, and can be coupled easily to acrylated HGPs via the 
same Michael addition described above. HGPs with varying 
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particle diameter and average interior pore size will be 
synthesized by inverse emulsion polymerization, following 
our previously reported procedures with minor revisions. 
The amount of HP/HS conjugated to HGPs may be varied 
and the % incorporation may be analyzed collectively by 5 
alcian blue staining, toluidine blue assay and chemical 
analysis. 
The simplicity of particle synthesis, and the defined 
biological activities of the constituent building blocks, ren-
der the HS/HP-decorated, HGP system an attractive candi- 10 
date for the sustained release of the proposed GFs. GF 
binding and release for all GFs may be quantified using 
immunochemical (ELISA) and radiolabelling assays. The 
content of the HGPs may be systematically varied to enable 
the sequential release of HBGFs. HGPs with a higher 15 
amount of PlnDI(HS) may be needed for the delayed release 
14 
gates, stabilized by disulfide bonds. The cysteine thiol in the 
multiblock copolymer may be diluted by CuAAC of 
N3 -PEG-N3 with a mixture of cysteine-containing and cys-
teine-lacking peptide monomers. The modular nature of the 
design, coupled with the chemical nature of the synthesis, 
may permit facile adjustment of mechanical, morphological, 
and biological properties of the resulting matrices. PlnIV 
peptide may be conjugated to HA-AC to provide essential 
cues to cells entrapped in the Cell-MMs. If PlnIV peptide 
alone is not sufficient to elicit cell attachment and assembly, 
laminin-derived peptide with a sequence of IKVAV and 
YIGSR or fibronectin-derived RGD can be integrated into 
hydrogels to reinforce the biological activity of PlnIV pep-
tide. FIG. 9 demonstrates HA bilayers with dimensions 
down to 200 µm. Standard micro fabrication methods may be 
used to produce bilayers with smaller dimension. 
The salivary gland is a complex glandular tissue built 
upon the core synthetic and secretory function of polarized 
salivary acinar cells, the directional pipeline established by 
of VEGF than for the release of FGFs. Within the FGF 
family, the affinity of different variants for HS/HP may be 
similar. Thus, careful titration of HS/HP content may be 
critical to attain a defined gradient for each FGF. The 
combined HA gel, embedded HGPs and conjugated GFs 
may instruct salivary cell organization and tissue integra-
tion. 
Successful engineering of functional salivary gland tis-
sues may require robust, yet soft and pliable matrices that 
foster cell growth and differentiation, facilitate cell assembly 
and induce branching morphogenesis and tissue integration. 
From modular building blocks, 3D instructive matrices may 
20 the assembled ductal cells, and the stimulated MECs. Regu-
lated saliva transport into the oral cavity absolutely depends 
upon glandular integration with vascular and autonomic 
nervous tissue. The biological principles by which this 
assembly occurs during salivary gland organogenesis are 
25 increasingly well understood. This disclosure re-establishes 
these principles to the best of sum current knowledge in a 
modular tissue engineering approach to build a neotissue 
3D-ST ready for pre-clinical surgical implantation. 
Purified primary human salivary CK5+ progenitor cell-be constructed by mixing HA-AC and [PlnDIV-PEGJn with 
GP-containing HGPs at varying proportions. Hydrogel 
crosslinking kinetics may be monitored via bulk solution 
rheology to determine gelation time and moduli of the stably 
crosslinked gels. Gels may be characterized via standard 
compression tests to probe stress-strain behaviors, stiffness 
and toughness. GF diffusion within hydrogel networks 
relates to hydrogel microstructure, and may be probed using 
fluorescently labeled GFs in fluorescence recovery after 
photobleaching (FRAP) self-diffusion studies. Bulk release 
studies will measure GF release rates from gels. Cytocom-
patibility of the composite, hybrid gels may be analyzed by 
mixing cells with the modular gel components for in situ 
gelation, and assaying for viability via live/dead staining. 
30 enriched populations (as shown in FIGS. 9A and 98) with 
long term (> 100 day) growth potential that appears to be 
limited only by time and space when cultured in 3D HA 
hydrogels were developed. From these, human ductal and 
MECs with appropriate morphology and marker expression 
35 were obtained and cultured. (See FIGS. 9C and 9D.) Sali-
vary acinar cells in 3D HA hydrogels such that they form 
stable tight junctions by multiple criteria were reassembled. 
(See FIG. 10) Consistent lumen formation in acinar-like 
cells grown in 3-D was established. The synthesis and 
40 secretion of salivary amylase by salivary acinar cells in 2D, 
2.5D, and 3D was demonstrated. Responses of salivary cells 
to both muscarinic and ~-adrenergic stimulation (See FIG. 
16) were demonstrated. Conditions for transfections of cul-
tured acinar-enriched cells with red fluorescent protein 
Cells may be encapsulated within miniature hydrogel 
modules for later reassembly into larger, more complex 
structures. As shown in FIG. 8, thin silicone (PDMS) slabs 
may be cured and a laser cutter may be used to create 
templates with scalable x,y features ranging from 200 µm to 
several millimeters, and similar z thickness. These PDMS 
molds are easily sterilized and reusable, with no changes in 
template dimensions. HA hydrogels may be gelled within 50 
these molds, and easily removed after gelation (See FIG. 
SC). Adjacent bilayers with distinct cellular and biological 
components may be gelled (See FIG. SD). PDMS molds 
may be adhered to glass substrates, and individual wells may 
45 (RFP) were developed. Conditions for reproducible induc-
tion of angiogenesis using FGF-2 and VEGF were estab-
lished. 
Strategies to build an artificial salivary gland suitable for 
implantation may incorporate the following 7 features: 1) 
instill cellular growth potential without overgrowth; 2) trig-
ger and retain the differentiated, properly assembled 
branched state involving multiple cell types; 3) build and 
retain tight junctions among polarized acini; 4) create and 
retain proper luminal structures for accumulation and trans-
port of salivary components (fluid and protein); 5) support 
long term synthesis and regulated, directional secretion of 
salivary components; 6) establish and retain proper assem-
bly of ECM components, cell and tissue barriers; and 7) 
recruit vascular and nervous tissue to maintain the gland and 
be partially filled with a mixture of HA-AC, [PlnDIV-PEGJn 55 
and cells. As the HA precursors crosslink, cells may be 
encapsulated within the hydrogel network over 15-30 min. 
The molecular weight of the HA precursors may be tuned to 
allow for rapid diffusion, efficient crosslinking, and optimal 
mechanical properties. 60 ensure tissue integration. 
If disulfides interfere with the CuAAC reaction, acet-
amidomethyl group-protected cysteine may be used instead 
and the reactive thiol may be revealed by iodine oxidation 
upon completion of the condensation polymerization. The 
proposed multi block crosslinker may contain a cysteine thiol 65 
on every peptide repeat. The close proximity of the thiol 
groups may cause the multiblock copolymers to form aggre-
In 2D culture, salivary acinar cells can senesce, a property 
that limits efforts to functionally reconstitute a full gland. 
Such growth limitations are not found in 3D HA hydrogels 
(as shown in FIG. 11), in which cells continue to grow over 
three months and appear to be limited only by space con-
straints in the hydrogel. Recent reports indicate that long-
term survival of the progenitor cell population that continu-
US 9,642,941 B2 
15 16 
Functional neotissue glands must advance beyond spheri-
cal lumen to initiate directional delivery of secretory prod-
ucts and recreate the differentiated roles of fluid producing 
acinar and fluid resorbing ductal cells. Recent work identi-
fied the specific roles ofFGF7 and FGFlO in inducing ductal 
elongation and branching, respectively. These roles are tied 
to the cells' perceived gradients of each GF from a point 
source, defined by diffusion through ECM and controlled by 
their binding to HS (in Pin and other proteoglycans ). Similar 
responses to FGF7 from assembled acinar-like cells in the 
3D HA systems have been seen, indicating that they have 
functional Fgfr2b. When delivered through media, FGF7 
may induce overall larger spheroids (as expected, when 
FGF7 is not delivered from a directional point source). This 
ously reconstitutes the salivary gland through the life of the 
organism requires multiple stimuli, including signals from 
parasympathetic innervations. In particular, cytokeratin 5 
(CK5) progenitor cells positive for both muscarinic receptor 
Ml and epidermal growth factor receptor (EGFR) are main- 5 
tained through signaling by acetylcholine (ACh) or its stable 
analog carbamylcholine (CCh), and HB-EGF. It has been 
observed that, in 2D, the isolated primary human acinar cells 
are >99% CK5+ (as shown in FIG. 98) with moderate c-Kit 
expression. As these cells form assembled acini-like struc- 10 
tures in the 3D HA hydrogels (as shown in FIG. 10), CK5 
expression is retained, along with expression of Musashi-1 
(Msi-1), and peripheral c-Kit. Msi-1 and c-Kit are widely 
described as markers for cells with progenitor and/or pro-
liferative potential. 15 response suggests that the acinar-enriched cell populations 
in the hydrogels retain proliferative potential and have not 
reached a post-proliferative stage of terminal differentiation. 
HGPs are an optimal mechanism for directional controlled 
HGPs pre-loaded with HB-EGF and isolated acinar-en-
riched cells may be embedded within HA microgels. Cul-
turing these MMs with varying CCh levels and varying 
HB-EGF release rates may allow for the determination of if 
a stable CK5+ population is maintained or enhanced in the 20 
acinar-enriched and/or ductal-enriched cultures during long 
term culture. The effects of varying these factors may be 
assessed by measuring cell proliferation (via PicoGreen) and 
staining for CK5, c-Kit, Msi-1, Ki67 (proliferation), and 
phenotypic markers Fgfr2b, CK19, and a-amylase. Cell 25 
response to CCh and HB-EGF stimulation may be quanti-
fied, either through in situ immunostaining and imaging of 
cell-MMs, or through cell release from the HA gels, fol-
lowed by flow cytometry. The necessity of co-culture with 
MECs and/or ductal cells to maintain acinar cell growth and 30 
differentiation may also be assessed. Best practices for 
ensuring growth of salivary cells in Cell-MMs and for 
maintenance of the progenitor cell population needed to 
resupply 3D-STs post-implantation may be established. 
Tight junction formation may be a hallmark of epithelial 35 
cell-cell interaction, and is well-characterized in salivary 
gland morphogenesis. Primary acinar-like cultures in HA 
quickly organize (-6 days) to form stable spheroids with 
defined lumen, apoptotic interior cells, and a gradually 
expanding diameter (as shown in FIG. 14). Pin in basement 40 
membranes is key to acini formation in developing glands, 
and enhanced spheroid formation through the covalent 
incorporation of PlnDIV peptide into the HA matrix has 
been observed. It has been shown that epithelial cells 
preferentially interact with this peptide, and that salivary 45 
acinar cells organize in PlnDIV-modified HA matrices lead-
ing to (a) enhanced lumen formation and (b) expression of 
tight and/or adherens junction markers (E-cadherin, 
~-catenin, claudin-1, Z0-1) (as shown in FIG. 15). 
PlnDIV-functional copolymers may be diluted with plain 50 
PEG, to maintain a constant gel crosslink density. PlnDIV 
concentration may be varied in two ways (as shown in FIG. 
13): (a) varying the overall PlnDIV:PEG molar ratio within 
each gel, and (b) holding PlnDIV:PEG constant, but varying 
the number of PlnDIV peptides per copolymer chain. The 55 
latter experiment (b) may identify the impact on cell behav-
ior of high local (i.e. clustered) PlnDIV peptides, which 
replicates their presentation in the 21 lg repeats of Pin DIV. 
This range of experiments is made possible by the use of 
Cell-MM microgels, which are easily replicated in high 60 
numbers for multiple experiments with high throughput, and 
easily imaged. Cell response can be quantified by immu-
nostaining of cell-MMs for tight and/or adherens junction 
markers (E-cadherin, ~-catenin, claudin-1, Z0-1) and HA 
receptors (RHAMM, CD44), measurement of acinus size/ 65 
number of time, and qualitative observations of acinus 
morphology. 
delivery of FGF7 and FGFlO. 
A second layer of HA hydrogel, containing HGPs loaded 
with FGF7 and/or FGFlO may be added. In this two-step 
modular process, acinar cells may be encapsulated in an HA 
"bottom layer" with the proper levels of CCh, HB-EGF 
HGPs, and PlnDIV. After gelation, a second thin layer of HA 
with FGF7/10-HGPs may be gelled above. Providing a 
directional mitogen gradient for the salivary cells may 
promote the formation of more complex, asymmetric struc-
tures, which may more accurately replicate native tissue. 
FGF7/10 levels may be varied by total amount, and by 
release rate. These two-layer systems may be assessed for 
morphological changes ( e.g. aspect ratio, bud ratio), and 
differential immunostaining at the distal edges vs. the proxi-
mal origin, and may be compared to control systems with 
FGF7/10 HGPs co-mixed within a single layer. 
Cues from ECM and neighboring cells may provide 
essential information to initiate and maintain stable long 
term differentiation of gland structures arising through pro-
cesses of branching morphogenesis. In the breast, inside-out 
acini reverse to correct stable polarity in the presence of 
MECs or a bioactive laminin-based peptide mimetic. Devel-
opmental studies showed similar invasion of epithelial pre-
cursors into a neighboring mesenchymal space, following 
GF cues from mesenchyme. The expanded 3D cultures 
already maintain many features expected of functional 
glands including stable tight junctions, enzyme production, 
and ion and water channels, an exception being their lack of 
final apical distribution of Mucl, a late polarization marker 
(See FIG. 16). 
Cultured MECs may be seeded with FGF7/10 HGPs in 
the "upper" layer of an HA bilayer. By creating a secondary 
HA layer above our acinar/ductal system, this may allow for 
sequential timing of acinar/ductal pre-organization in the 
bottom layer, prior to advancing into the upper MEC com-
partment. Laminin and/or PlnDIV peptide motifs may be 
covalently bound in the upper layer as needed, to promote 
MEC/ECM adhesion. Admixing of the two layers may be 
used for comparison. Each cell type can be fluorescently 
labeled to identify their movement, morphology, and asso-
ciation throughout the gels. Cell association among the 
seeded populations may be assessed, as well as the redis-
tribution of Mucl, to correct luminal orientation. 
FIG. 16 demonstrates the expression of ~1 and ~2 adren-
ergic receptors, and the M3 muscarinic receptor in spheroids 
assembled in HA hydrogel cultures. While staining was 
moderate and diffuse in 2D cultures, its intensity and local-
ization within cell aggregates in HA hydrogels was robust 
and paralleled the staining observed in native tissue. Treat-
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ment of assembled spheroids in HA with norepinephrine 
induced granule formation and robust a-amylase staining at 
the cell periphery and within the secretory route, indicative 
of a secretory exocytic response, while ACh treatment 
induced Ca2 + spikes (measured by Fluo-4) within the cells, 
indicative of a Ca2+ -based second messenger response. 
These responses were observed in assembled spheroids in 
HA hydro gels, but not in 2D cultures or isolated cells on HA, 
emphasizing the importance of spheroid assembly and tight 
junctions. 
PEG-PlnDIV synthesis is based on well-developed chem-
istry. If problems arise, acrylated or thiolated PlnDIV may 
be synthesized for direct pendant incorporation into the HA 
network. For FGF7 experiments, it is known that specific 
interactions occur between FGF7 and the N-terminal seg-
ment of Pin domain III. PlnDIII core protein fragments may 
be incorporated into HGP particles as a secondary FGF7 
source if warranted. FGF7/10 HGPs may affect MECs in the 
upper layer of cell-MMs, as is known in other glandular 
tissues. FGF7/10 levels may be modified as needed, or 
control trials may be conducted with empty HGP to trouble-
shoot the upper layer if MECs are adversely affected. 
Restoration of glandular tissues has lagged behind recent 
progress in bone, cartilage and bladder engineering, in part 
due to the increased cellular complexity of the tissue. In vivo 
studies may implant engineered human salivary gland pro-
totypes of progressive complexity, and test their function at 
each step. These studies may yield an experimental frame-
work for assessing function in vivo for salivary tissues. 
Optimized MMs and 3D-STs (See FIGS. 1 and 2) may be 
implanted in a rat model and monitored over time. Outcome 
measures may assess the functions that must be reestab-
lished by the implant and the known structural features of 
native salivary tissue. Immunocompetent Sprague-Dawley 
rats may be used for cell-free MMs, while the hooded T cell 
deficient athymic nude rat may be the model for cell-MMs, 
because it is of sufficient size to host surgical implants and 
its immunocompromised status allows use human cell use 
without rejection. 
HA gels (acellular, GF seeded, and acinar cell seeded) 
have successfully been implanted subcutaneously in the 
back of nude rats and in the 314 resected parotid gland model 
that we developed with minimal detriment to the host. None 
of these constructs induced inflammation, but unvascular-
ized gels were degraded significantly after 4 wks in the back 
(See FIG. 17B). Encapsulated CK5+ cells remained viable 
for >3 wks and a majority of implanted spheroids continued 
to produce amylase, express cytokeratins, and maintain 
luminal structure (See FIGS. 17C and 17D). To assess the 
ability of HGPs to trigger angiogenesis into the HA hydro-
gels, gels containing VEGF loaded HGPs were implanted in 
the 314 resected parotid bed. In 1 wk, implants in the parotid 
bed showed a robust increase in blood vessel formation and 
infiltration into the gel implant (See FIG. 17F). Cell-MM 
and 3D-ST studies thus may include cells fully embedded in 
various test constructs of hydrogel. Based on the initial 
animal studies, viability or biocompatibility problems are 
not expected with HA, Pin-HA constructs, or human acinar 
cells in the nude rat system or cell free modified hydrogels 
in immunocompetent rats. 
Proof-of-principle studies in rats implanted with 3D-ST 
may be conducted. These studies may evaluate implant 
viability, integration into the surrounding tissue, recruitment 
18 
same surgery with engineered 3D-STs and outcomes assess-
ment (structure, function, tissue integration). At UD, an 
IACUC-approved protocol is in place for these studies 
( details in Vertebrate Animals). A surgical model was devel-
5 oped in which 314 of the left parotid gland of 5 male rats per 
group ( consistent with similar pilot studies is resected, 
leaving the right side intact as a control. Resected salivary 
gland tissue does not regenerate in humans, and is not 
expected to regenerate in other mammals. However, the 
10 remaining salivary duct structure and function may be 
preserved, as has been shown for ducts blocked by stones. 
Sterile dissection of the rat requires a small incision with 
exposure of the rat parotid and preservation of neural tissue. 
3D-STs are embedded in the left rat parotid gland, a proce-
15 dure to date with minimal detriment to the animal subjects. 
Prior to RT, patients can undergo ultrasound guided fine 
needle aspiration to visualize normal parotid parenchyma 
free of tumor. Under the !RB-approved protocol, tissues may 
be secured from consenting patients, and these tissues may 
20 be immediately processed in the laboratory to release, sort, 
and culture the CK5+ progenitor cell populations that con-
tain the various acinar, ductal, and MEC populations. A bank 
of these cells from multiple patients, taken from multiple 
gland sites, may be maintained and these cells may be used 
25 to generate all preliminary data. 
Implanted neotissues of any significant size require a 
blood supply for their long-term survival in vivo. Neoves-
sels must be able to reach any encapsulated cell-MMs. 
Increases in angiogenesis into the HA hydrogels containing 
30 VEGF-loaded HGPs (200 ng/mL) over control hydrogels 
implanted in the parotid bed have been demonstrated (See 
FIG. 17F). The HGPs may be tuned to recruit vascular 
supply in vivo, and quantifying the resultant capillary struc-
ture. The volume of implanted hydro gel may also be varied, 
35 to insure that neovessels can reach any cell-MM structures 
within. 
HGPs may be pre-loaded with both VEGF and FGF2 to 
induce capillary ingrowth from surrounding tissue, a com-
bination found to be synergistic in stimulating angiogenesis. 
40 A pre-set number of HGPs, at three GF concentrations (0, 
10, 100 ng/mL ), may be gelled within HA networks at two 
volumes (150 and 300 µ!) to form an HA-HGP structure. 
HA-HGP may be implanted in 4 month old immune intact 
Sprague-Dawley rats after 314 left parotid resection. After 1 
45 and 4 wks (earlier in case of adverse event), implants may 
be harvested, processed, immunostained, and assessed for 
angiogenesis in the HA-HGPs by the presence of vascular 
elements (CD31/PECAM+ ), and their length, branches, and 
nodes. Histologic sections may be stained for inflanimation 
50 or immune cell response (T cell, neutrophil, macrophage). 
Any combination causing adverse host immune responses 
may be discarded. HA-HGPs with the best host response 
profiles ( quantified vessel length, branching) may be used 
for cell-seeded implant studies in the parotid in nude rats. 
55 The distance of accessible vascularization may be used to set 
the final volume for later 3D-STs. 
A series of comparative studies may incorporate the 
bilayered MM structures, which employed HGPs loaded 
with HB-EGF in one layer, and FGF7/10 in the other. MMs 
60 may be encapsulated within HA to form larger 3D-ST 
modular objects. Cell-free 3D-STs may be implanted in the 
left parotid bed of 4 month old 314 resected Sprague-Dawley 
rats and allowed to mature for 4 weeks if there are no 
of vascular support (via our controlled GF release methods), 
and restoration of salivary function. The strategy is to 65 
surgically simulate acinar cell loss through controlled 
parotid resection, with subsequent replacement during the 
adverse effects. After sacrifice, implants may be scored for 
vascularization and immune response. 
Optimized angiogenic HGPs and MECs may be system-
atically introduced within cell-MMs to determine if these 
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human-specific antibodies against a-amylase, IgA, mucins, 
albumin, praline-rich, histatin-rich and tyrosine-rich pro-
teins; (3) viscosity, pH and electrolytes; (4) quantification of 
functional amylase production by chromogenic assay Ani-
supporting mechanisms are necessary and/or sufficient to 
promote acinar retention, organization, and phenotype 
expression in vivo. Cell-MMs may employ RFP-transfected 
acinar progenitor-enriched cells for monitoring over time in 
implanted rats in vivo via IVIS imaging (Caliper). Fluores-
cence has previously been detected from as few as 1000 
cells, with strong signal from >5000 cells if no hair was 
present, thus nude rats are ideal. Fluorescence intensity may 
correlate to growth of implanted RFP-labeled cells in vivo. 
5 mals will be euthanized and implants will be analyzed 
histologically for tissue response, integrity, stability and 
biointegration of the implanted 3D-STs. 
All quantitative data from outcome measures may be 
analyzed statistically via calculation of means, standard 
As shown in the Vertebrate Animals table, the in vivo 
experiments may be divided into four implantation groups, 
varying two parameters: (a) 3D-STs with/without angio-
genic HGPs and (b) 3D-STs with/without MEC support 
cells. All groups may be implanted in the left parotid bed of 
10 deviations, and standard errors. To determine significance, 
Student's two-tailed t-tests or Analysis of Variance 
(ANOVA) may be used. Significance may be defined as a 
confidence interval greater than 95% (p<0.05). 
A successful, functional 3D-ST prototype may have 
15 greater protein, electrolyte, and water production after 4 wks 
implantation, with lower viscosity and higher pH. 3D-STs 
may show long term stability, biointegration, and no over-
growth. Cell differentiation should be maintained, and nei-
314 resected nude rats, monitored at 1, 4, 7, or 10 wks by in 
vivo IVIS imaging. At experiments end, implants may be 
retrieved and quantified for vascularization as before. RFP+ 
cell retention and co-localization with specific biomarkers 
may be quantified by IHC: (1) progenitor markers (CK5, 
c-Kit, Msi-1); (2) proliferation marker Ki67; (3) ratios and 20 
location of a-amylase/K14/K19+ cells (acinar/MEC/ductal 
cell differentiation); (4) FGFR2b. Morphologic analysis may 
assess if the acinar-cell seeded Cell-MM triggers and 
retains: 1) differentiated and properly assembled acini-like 
structures; 2) tight junctions among polarized acini (E-cad- 25 
herin, ~-catenin, claudin-1, Z0-1 staining); 3) proper lumi-
nal structures for accumulation/transport of salivary com-
ponents (aquaporin); 4) assembly ofECM components, cell 
and tissue barriers; 5) host salivary cells; 6) ductal cell 
differentiation in situ. Any connections between the 30 
implanted structures and the innate salivary and vascular 
supply may be highlighted and quantified. All structures 
may be compared to intact salivary tissues in the same 
animal. Supporting work may utilize Western blot and 
RT-PCR to qualitatively and quantitatively measure acinar 35 
cell phenotype including basement membrane protein 
expression and secretion, tight junction proteins, water chan-
nel protein aquaporin-5, stress fibers, activated focal adhe-
sion kinase, and a-amylase as in our previous published 
work. TUNEL and/or caspase staining may assess apoptosis. 40 
Signs of necrosis, loss of cell viability, or host cell infiltrate 
that may occur even in the absence ofT cells may be looked 
for. It is hypothesized that Cell-MMs, implanted without 
3D-ST angio support, may not fare as well as the full 3D-ST 
assemblies. The survival of 3D-STs in the salivary bed may 45 
be assessed. It may be determined whether complex cell 
mixtures or acinar enriched cell populations alone are 
needed to form neotissues. Also, the host response for 
optimal biointegration may be tuned. It may also be possible 
ther necrosis nor fibrosis should occur. Acellular 3D-STs 
supplied with GFs may stimulate remaining endogenous 
progenitor cells to repair the gland, a potential outcome that 
also would be a success. 
FIG. 17 shows HA stability in vivo, human acinar cell 
retention, phenotypic lumen formation and amylase expres-
sion, and angiogenesis from the host. HA stability/degrada-
tion rate can be tuned through crosslink density if needed. 
Implanted human cells (MECs or acinar cells) can be 
identified after sacrifice using human-specific ribosomal 
RPL29 antibody, should RFP labeling fail. Because the 
resected parotid model does not create a condition identical 
to patients undergoing RT, future studies could use alternate 
facilities to irradiate the rodent salivary bed and follow 
acinar cell and tissue destruction. A neural stimulation to the 
implant is important. 3D-STs may be analyzed for innerva-
tion into the implant, by the presence and length of neuronal 
axons (via neuronal markers). If the implant fails to have any 
signs of innervation, HGPs can be modified to deliver NGF. 
Example 3 
This example illustrates salivary acinar-like cell assembly 
and functional neurotransmitter responses within 2.5D and 
3D HA hydrogel systems both in vitro and in vivo. We 
reported the isolation of acinar-like cells from human sali-
vary tissues, and their self-assembly into 3D acini-like 
structures when cultured on 2.5D hyaluronic acid (HA) 
hydrogels modified with ECM-derived bioactive peptide 
fragments. (Pradhan, S., C. Liu, C. Zhang, X. Jia, M. C. 
Farach-Carson, R. L. Witt. Lumen formation in 3D cultures 
of salivary acinar cells. Otolaryngology-Head and Neck 
Surgery, 2009). We recently employed a 3D HA-based 
culture system to organize salivary acinar-like cells into 
spherical structures. 
The development of a tissue-engineered, implantable sali-
to determine if CK5+ populations expressing proliferative/ 50 
progenitor markers can survive long term to provide the full 
resource for permanent in situ restoration of gland function 
(vs a need to resupply multiple more differentiated cell 
types), and potentially resolve unanswered questions in the 
current literature. 55 vary gland will greatly benefit patients suffering from xero-
stomia. This example compares the ability of a 2.5D and a 
3D hyaluronic acid (HA)-based culture system to support 
functional salivary units capable of producing fluid and 
After evaluating 3D-ST function on the cellular level in, 
full in vivo function may be assessed through a series of 
physiological assessments. Cell-MMs within 3D-STs may 
be varied across four groups (0, 10, 50, or 250 Cell-MMs per 
3D-ST) to determine the minimum number needed to restore 60 
salivary function. Each group may be implanted in 314 
resection surgeries in nude rats. At 1 and 4 wks after 
implantation, rats from each group may be anesthetized and 
injected with pilocarpine to induce salivation. Saliva may be 
obtained from the oral cavity using a micropipette and 65 
assessed using the following assays: (1) BCA assay (total 
salivary protein concentrations); (2) Western blot with 
phenotypic proteins. Parotid cells seeded on 2.5D, as well as 
those encapsulated in 3D HA hydrogels, self-assembled into 
acini-like structures and expressed functional neurotrans-
mitter receptors. Structures in 3D hydrogels merged to form 
organized 50 µm spheroids that could be maintained in 
culture for over 100 days and merged to form structures over 
500 µm in size. Treatment of acini-like structures with the 
~-adrenergic agonists norepinephrine or isoproterenol 
increased granule production and a-amylase staining in 
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treated structures, demonstrating regain of protein secretion. 
Upon treatment with the M3 muscarinic agonist acetylcho-
line, acini-like structures activated the fluid production path-
way by increasing intracellular calcium levels. The increase 
in intracellular calcium seen in structures in the 3D hydrogel 5 
culture system was more robust and prolonged than that in 
2.5D. To compare the long-term survival and retention of 
acini-like structures in vivo, cell-seeded 2.5D and 3D hydro-
gels were implanted into an athymic rat model. Cells in 2.5D 
failed to maintain organized acini-like structures and dis- 10 
persed in the surrounding tissue. Encapsulated cells in 3D 
retained their spheroid structure and structural integrity, 
along with the salivary biomarkers and maintained viability 
for over three weeks in vivo. This example identifies a novel 
hydrogel culture system capable of creating and maintaining 15 
functional 3D salivary spheroid structures for long periods 
in vitro that regain both fluid and protein secreting functions 
and are suitable for tissue restoration. 
Cell Culture 
Parotid gland tissue was collected from patients aged 20 
40-55 years undergoing surgery under an !RB-approved 
protocol and consent from both Christiana Care Health 
Systems and University of Delaware. Homogeneous popu-
lations of proliferating acinar-like cells were obtained from 
tissue explant outgrowths and tissue dissociation procedures 25 
as previously described. (Pradhan, S., C. Liu, C. Zhang, X. 
Jia, M. C. Farach-Carson, R. L. Witt. Lumen formation in 
3D cultures of salivary acinar cells. Otolaryngology-Head 
and Neck Surgery, 2009; Pradhan, S., C. Zhang, X. Jia, D. 
D. Carson, R. Witt, M. C. Farach-Carson. Perlecan domain 30 
IV peptide stimulates salivary gland cell assembly in vitro. 
Tissue engineering Part A 15, 3309, 2009.) Parotid gland 
tissue specimens were minced to a slurry that was suspended 
in serum-free Hepato-STIM medium (BD Biosciences Dis-
covery Labware, Bedford, Mass.) and distributed in a six- 35 
well plate (BD Falcon™, Franklin Lakes, N.J.) and left 
untouched for 7 days, then supplemented with Hepato-STIM 
growth medium until cells migrated out of the tissue 
explants. Confluent cells were passaged with 0.05% (w/v) 
trypsin EDTA (Invitrogen). 0.5 mg/mL of trypsin soybean 40 
inhibitor (Sigma, St. Louis, Mo.) stopped the trypsin activ-
ity. Cells were plated at a dilution of 1: 10. Cells in passage 
3-4 were used for all experiments. 
2D Hydrogel Preparation 
HA was modified to contain methacrylate groups by 45 
reacting it with glycidyl methacrylate (GMA), as described 
previously (Jia, X. Q., J. A. Burdick, J. Kobler, R. J. Clifton, 
J. J. Rosowski, S. M. Zeitels, R. Langer. Synthesis and 
characterization of in situ cross-linkable hyaluronic acid-
based hydrogels with potential application for vocal fold 50 
regeneration. Macromolecules 37, 3239, 2004.) This photo-
crosslinkable HA (HAGMA) was crosslinked into hydrogels 
in the presence of photoinitiator, 30% (w/v) 2,2-dimethoxy-
2-phenylacetophenone (DMPA) in l-vinyl-2-pyrrolidinone 
(NVP). Hydrogels were generated in cell culture inserts 55 
(Millipore, Billerica, Mass., diameter: 12 mm, pore size: 0.4 
µm) and placed in 24-well plates (Coming, Lowell, Mass.). 
Polymerized gels were swollen in 1 xPBS for 24 h. Salivary 
acinar-like cells were seeded on the hydrogels (lxl05 cells/ 
200 µL hydrogel) and Hepato-STIM growth media was 60 
added both inside and outside the culture insert. 
3D Hydrogel Preparation 
An HA-based Hystem™ hydrogel system (Glycosan Bio-
systems, Salt Lake City, Utah) was utilized to encapsulate 
salivary cells in 3D. Cells (lxl05 cells/1500 µL hydrogel) 65 
were mixed with the HA-thiol component of the kit. Extra-
link [poly( ethylene glycol)-diacrylate] was added directly to 
22 
this mixture, and mixed thoroughly before plating on 12 mm 
cell culture inserts (Millipore) placed in 24-well plates. 
Plates were placed in a 37° C. incubator for partial polym-
erization. After 15 min, a small amount of Hepato-STIM 
growth media was added to the outside chamber of the 
culture insert and the gel polymerized for 10 minutes. Upon 
complete polymerization, culture media was added over the 
hydrogel. 
Analysis of Structure Growth 
lxl05 cells/hydrogel were seeded on the 2.5D and in the 
3D HA hydrogels. Acini-like structures were counted from 
each quadrant of three such hydrogels, for every time point. 
Hydrogels were supplemented with 300 µL of media every 
3 days for the first 12 days. After about 12 days in culture 
when the hydrogels are full oflarger spheroid structures that 
metabolize rapidly, the media is exchanged every 3 days. 
Cell Proliferation Measurements 
lxl05 cells/hydrogel were seeded in 3D and were main-
tained as mentioned above. Hydrogels were analyzed at Day 
1, 6, 12, 21 and 26. On the day of analysis, media was 
removed and the hydro gels were washed with 1 xPBS. 30 µL 
of30 kU/mL hyaluronidase type VI-S (Sigma) was added to 
each gel and incubated at 37° C. for -2 h. The cells were 
then pelleted and washed with lxPBS. The cell pellet was 
resuspended in 200 uL oflysis buffer and cells were allowed 
to lyse for 30 min on ice. The solution was then centrifuged 
at 13,000 RPM for 20 min and the supernatant was used for 
further analysis. The Qubit™ dsDNA HS Assay Kit (Invit-
rogen) was used to measure dsDNA concentration using the 
Qubit® Fluorometer (Invitrogen). 
Immunofluorescence 
Primary antibodies were monoclonal claudin-1 (Zymed 
Laboratories, San Francisco, Calif.), polyclonal Z0-1 
(Zymed Laboratories), monoclonal ~-catenin (BD Trans-
duction Laboratories), monoclonal E-cadherin (Abeam, 
Cambridge, Mass.), monoclonal Ki-67 (BD Pharmingen™) 
polyclonal M3 muscarinic receptor (Santa Cruz Biotechnol-
ogy, Santa Cruz, Calif.), polyclonal ~1 adrenergic receptor 
(Santa Cruz Biotechnology), polyclonal ~2 adrenergic 
receptor (Abeam) and polyclonal a-amylase (Sigma, St. 
Louis, Mo.). Secondary antibodies Alexa 488 and Alexa 568 
(Invitrogen, Carlsbad, Calif.) against mouse or rabbit IgG 
were used. Nuclei were stained with Draq5 (Biostatus, 
Leicestershire, United Kingdom). 
Staining of tissue sections and 2D cultured cells was 
performed as previously described (Pradhan, S., C. Zhang, 
X. Jia, D. D. Carson, R. Witt, M. C. Farach-Carson. Perlecan 
domain IV peptide stimulates salivary gland cell assembly in 
vitro. Tissue engineering Part A 15, 3309, 2009). Briefly, 
tissue cryosections (8 µm) were fixed with cold 100% 
methanol, rehydrated with 1 xPBS and blocked overnight in 
3% (w/v) BSA in PBS. Sections were incubated with pri-
mary antibody at 37° C. for 45 min and washed in lxPBS 
for 30 min. Secondary antibody incubation was for 40 min 
at 37° C. followed by 10 min treatment with Draq5. Tissue 
sections then were washed with lxPBS for 30 min. Slides 
were mounted with Gel Mount and imaged on a Zeiss 510 
NLO LSM confocal microscope. 2D cultured cells were 
stained identically with minor changes. After methanol 
fixation, cells were permeabilized with 0.2% (v/v) Triton 
X-100 for 10 min and washed twice with lxPBS before 
blocking. Stained cells were covered with Gel Mount 
(Biomeda Corporation, Foster City, Calif.) and imaged by 
confocal microscopy. 2.5D hydrogels were stained in the 
same way as cultured cells. After staining, hydrogels were 
removed from culture inserts and placed cell-side down in 
8-well chamber slides (Lab-tek® Products, Nalge Nurre 
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International, Naperville, Ill.), covered with Gel Mount. 3D 
hydrogels were stained similarly. Each step during the 
staining of 3D hydrogels was prolonged by 50% to allow 
complete diffusion of liquids through the hydro gel. Cells on 
hydrogels were imaged by confocal microscopy. Negative 5 
controls omitted primary antibody. Primary antibodies spe-
cific for antigens expressed by other cell types present in the 
same tissues or cells served as negative controls for non-
specific binding. 
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stirred for an hour before electrospinning. Electrospun scaf-
folds were generated using an electrospinning unit, consist-
ing of a syringe pump (KD Scientific, Holliston, Mass.), a 
high-voltage power supply (Spellman, Hauppauge, N.Y.), 
and a rotating mandrel collector. The syringe pump gener-
ates a constant flow from the needle at 0.5 mL/h flow-rate. 
Electrospun scaffolds were crosslinked with glutaraldehyde 
(GA) (Electron Microscopy Sciences, Hatfield, Pa.) in the 
vapor phase for 19 h at a concentration of 25% (w/w). 
Functional Response: Exocytic Granule Production 10 Electro spun scaffolds with a fiber diameter of 600+/- ll O nm 
were used. Cells seeded (lxl05 cells/gel) on/in hydrogels were 
treated with varying concentrations (10 µM to 100 µM) of 
isoproterenol hydrochloride (Santa Cruz Biotechnology) 
and norepinephrine hydrochloride (Sigma), each of which 
induce granule production and exocytosis, for various time 15 
points from 15 min-2 h. After treatment, culture medium 
was removed and cells were fixed immediately with 100% 
methanol and stained with a-amylase for microscopic analy-
sis. 
Functional Response: Calcium Release Studies 20 
Intracellular calcium [Ca,] release studies utilized the 
calcium indicator dye, Fluo-4 (Invitrogen). Cells were 
seeded at lxl05 cells/gel in cell culture inserts as before. 
Cells on 2.5D and in 3D hydrogels were cultured for 12 
days. Fluo-4 was suspended in 0.8% (w/v) pluronic acid and 25 
mixed with 8 mL of lx Hanks' balanced salt solution 
(HBSS) without calcium. Cell-seeded hydrogels were incu-
bated with Fluo-4 suspended in pluronic acid for 30 min at 
The 3D hydrogel was not wrapped as the cells were fully 
encapsulated inside the hydrogel. Hydrogels were inserted 
in the incisional pocket and wounds closed with surgical 
clips. Animals recovered and resumed activity post-surgery. 
Rats were sacrificed at 11 day, 3-week and 4-week time 
points and the implants removed for analysis. Three 
implants per time-point were used in this pilot study. 
Results 
Acini-Like Spheroid Formation in 3D HA-Hydrogels 
Cells seeded in 3D hydrogels self-assembled into orga-
nized acini-like spheroids within 3 days. Spheroids grew 
until a critical size of -50 µm (-day 12) was reached, after 
which they merged and proliferated to form even larger 
structures (60-200 µm) (FIG. 18C, D). The progression of 
the growing acini-like structures is shown in FIGS. 18A-D. 
Tight junction proteins such as CL-1, Z0-1, E-cadherin, and 
adherens junction proteins such as ~-catenin hold these 
spheroids together (FIG. 18A-D). Spheroids larger than 40 
30 µm in diameter showed evidence of lumen formation via 
apoptosis of central cells (FIG. 18E). A representative 
brightfield image of an acinus-like structure is shown in FIG. 
18F. 
3 7° C. After 30 min, cells were washed twice with 1 xHBSS, 
and incubated for 30 min in HBSS. After loading and 
recovery, hydrogels were imaged using a Zeiss LSM 5-live 
high-speed confocal microscope. Baseline fluorescence was 
established for 30 sec at 488 nm. Cell-seeded hydrogels then 
were treated with various concentrations (ranging from 50 
µM-500 µM) of the muscarinic agonist acetylcholine chlo- 35 
ride. 2.5D hydrogels were flipped so that cells were on the 
bottom of the chamber slides. 50 µL of the agonist was 
added to the bottom of the chamber containing 50 µL 
medium. 3D hydro gels were suspended in 100 µL of 
medium and treated with 100 µL of agonist. Resulting 40 
increases in Ca, levels were captured in a series of image 
scans and by graph plot. 
Animal Studies 
Growth of Acini-Like Structures in HA Hydrogels 
Self-assembled acini-like structures formed within 1-3 
days of culture in both the 2.5D and the 3D hydrogel systems 
and continued proliferating (FIG. 19). Acini-like structures 
grew more quickly in 3D than in 2.5D. At a critical density, 
the acini-like structures in the 3D culture system began to 
merge and the number of spheroids plateaued (FIG. 19). 
Cells seeded at a higher density in the hydrogels merged 
quicker and formed larger spheroids. However, these spher-
oids often were less organized than those seeded at lower 
densities. Spheroids in 3D were stable over 100 days and 
45 structures as large as 500 µm were observed. Structures in 
2.5D rarely merged, were less organized, and grew much 
slower than those in 3D (FIG. 19). 
Animal studies were performed as approved by the 
IACUC at the University of Delaware. Hydrogel biocom-
patibility studies used immunocompetent three-month old 
male Sprague Dawley rats to ensure that hydrogel material 
was not immunogenic and biodegraded over time. Male 
athymic hooded rats (Harlan Laboratories) aged 3-4 months 
were used for all implantation studies involving human 50 
cells. Rats were anesthetized in a closed chamber, purged 
with 0.5-1.0 Umin oxygen supplemented with 3-5% isoflu-
rane, and kept asleep using a nose cone at 0.5-1.0 Umin 
oxygen with 1-3% isoflurane. Backs were shaved and 
cleaned with alcohol wipes, and subsequent surgical proce- 55 
<lures conducted under a laminar flow hood. A 1 cm incision 
was made on the back and a small pocket was created for the 
implant. The 2.5D hydrogel was wrapped with a piece of 
electrospun gelatin membrane to avoid dispersion of cells 
cultured on it. Fabrication of electrospun gelatin scaffolds 
has previously been described (Sisson 2010 and Sisson 
2009). 25% gelatin (w/w) (courtesy of Eastman Kodak 
Corporation, Rochester, N.Y.) was dissolved in a solvent 
containing acetic acid (ACS reagent, 99.7%, Sigma Aldrich, 
Milwankee, Wis.), ethyl acetate (Fisher Scientific, Pitts-
burgh, Pa.), and distilled water at a ratio of 60:10:30. The 
gelatin solution was incubated overnight at 37° C. and 
Proliferation of acini-like structures in 3D was measured 
by quantifying their dsDNA over time as well as via staining 
with the proliferation marker, Ki67 (FIG. 19B, C, D). A 
linear increase in proliferation was observed among cells 
growing in 3D HA hydrogels (FIG. 19B). Acini-like struc-
tures cultured for over 48 days in 3D continued to proliferate 
(FIG. 19D). Ki67 staining was observed in cells located near 
the periphery of the structures (FIG. 19C, D). 
Profiling Expression of Neurotransmitter Receptors in 
Glandular Tissue and Cultured Cells in 2D, 2.5D and 3D 
We profiled expression of the neurotransmitter binding 
receptors present on salivary acinar-like cells that activate 
60 pathways associated with salivary fluid secretion and protein 
synthesis. Salivary gland tissue sections, cells cultured in 
2D, 2.5D, and those encapsulated in 3D were stained for 
neuroreceptors. Acinar-like cells cultured in 2D showed 
diffuse cytoplasmic expression of ~1 and ~2 adrenergic 
65 receptors, while the M3 muscarinic receptor was seen on the 
cell membranes of some acinar-like cells in 2D (FIG. 20A, 
B, C). Self-assembled salivary acinar-like cells cultured on 
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2.5D hydrogels expressed the ~2 and M3 receptors in the 
cytoplasm and on the cell membranes (FIG. ZOE, F). ~1 
receptor expression was seen on the cell membrane of some 
acinar-like cells in 2.5D (FIG. 20D). Organized spheroid 
structures encapsulated in 3D expressed all three receptors 5 
on their basolateral membranes (FIG. 20G, H, I). Some M3 
muscarinic receptor was expressed on the lateral membranes 
of cells (FIG. 201). As expected, glandular tissue sections 
showed expression of ~1, ~2 and M3 muscarinic receptors 
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concentration, on separate hydrogel cultures. Data were 
recorded from 3-4 acini-like structures each time. Repre-
sentative data sets are shown in FIGS. 27A and 27B. A 
representative confocal image of stimulated cells in 2.5D is 
shown in FIG. 27C. Negative controls performed with 
addition of saline buffer in place of the agonist failed to 
induce a calcium response. Positive controls used a hypo-
tonic solution to induce a calcium response. 
Treatment with 50 µM acetylcholine induced calcium 
oscillations that lasted over 20 minutes in spheroid struc-
tures encapsulated in 3D hydrogels (FIG. 27D). Acetylcho-
line (100 µM) induced similar oscillations among the 3D 
cultures (FIG. 27E). Compared to the response seen among 
2.5D cultures, the increase in [Ca2+] was quicker in 3D, 
on the cell membranes (FIG. 201, K, L). As seen among 3D 10 
spheroids, expression of M3 muscarinic receptor was seen 
along lateral membranes of glandular cells in tissue (FIG. 
20L). The encapsulated acini-like structures in 3D were 
more organized and better able to localize the receptor for 
stimulation by neurotransmitters. 15 where cells responded to acetylcholine treatment within 30 
seconds while cells in 2.5D took nearly 300 seconds. The 
duration of the oscillations was significantly longer in the 
3D cultures than in 2.5D suggesting that the apical calcium 
Stimulating Protein Secretion by Activating ~ Adrenergic 
Receptors 
Functionality of salivary acinar-like cells was assessed by 
response to neurotransmitter agonists. Norepinephrine bind-
ing to the ~ adrenergic receptors activates the protein 20 
secretion pathway. In this study, the sympathomimetic ~ 
adrenergic agonists, norepinephrine and isoproterenol, were 
used to stimulate protein production and exocytosis. Sali-
vary acinar-like cells cultured on/in hydrogels were treated 
with 50 µM isoproterenol for 15 min to 1 hr. After treatment, 25 
cells were immediately fixed and stained, then analyzed for 
granule formation and a-amylase expression. FIGS. 21-25 
quantify the extent of amylase response, using the intensity 
of fluorescence staining as a surrogate. Untreated acinar-like 
cells in 2.5D and 3D showed a basal level of secretory 30 
granules and a-amylase staining (FIG. 21A, D). Cells 
treated with 50 µM isoproterenol for 15 min showed a-amy-
lase near the membrane periphery, indicative of exocytosing 
vesicles (data not shown). Self-assembling structures with 1 
h isoproterenol treatment showed the presence of granules 35 
and robust a-amylase staining in their secretory route in 
both 2.5D and 3D (FIG. 218, E). Self-assembling acini-like 
structures treated with 50 µM norepinephrine also displayed 
multiple secretory granules in both 2.5D and 3D (FIG. 21C, 
channels might be open longer, allowing for enhanced fluid 
secretion (Table 1 ). A representative confocal image of 
responding cells in 3D is shown in FIG. 27F. Thus, cell 
response to acetylcholine agonist in 3D was faster, more 
intense, and more prolonged than cell response in 2.5D. 
Structures are Preserved in Hydrogels when Implanted In 
Vivo. 
TABLE 1 
Intracellular calciwn release data from acini-like 
structures treated with acetylcholine (ACh). 
Average 
Percent Peak Height Average Peak 
Sample Responders (Intensity) Length(s) 
2.5D 50 µM ACh 33% 58 ± 11 42 ± 21 
2.5D 100 µM ACh 22% 10 ± 3 46 ± 9 
3D 50 µMACh 43% 39 ± 6 164 ± 8 
3D 100 µMACh 16% 14 ± 8 180 ± 34 
To evaluate the long-term survival of the acini-like struc-
tures on 2.5D and those encapsulated in 3D hydrogels in 
vivo, cell-seeded 2.5 and 3D scaffolds were implanted in an 
athymic rat model. To avoid dispersion of cells from the 
2.5D hydrogel scaffold, the hydrogel with cells was wrapped 
in an electrospun gelatin membrane. 3D cell-seeded scaf-
folds were implanted without wrapping. Implants were 
analyzed at 11 days and 3 weeks. Some blood vessel 
infiltration (arrows) was seen within both implants in 2.5D 
and 3D (FIG. 28A-B, D-E). Despite the presence of the 
gelatin membrane, the cells in the 2.5D hydrogel scaffold 
F). Exocytosing granules stained in red for a-amylase are 40 
seen budding out from the cell membrane in FIG. 21C, E, F. 
Granule production has been quantified in FIG. 26. Upon 
stimulation, acini-like structures in 3D also secreted a-amy-
lase into the hydrogel (FIG. 21E, F). a-Amylase staining is 
quantified in FIGS. 23-25. This indicates that cells in 3D 45 
produce detectable levels of salivary proteins that can be 
secreted upon stimulation unlike those in 2.5D. Neurotrans-
mitter treatment was repeated >3 times and representative 
images are shown in FIG. 21. Over 50% of the cells in the 
treated samples displayed granules. 50 lost their assembly in acini-like structures and dispersed as 
single cells in the rat tissue surrounding the implant (FIG. 
28C). Encapsulated acini-like structures in the 3D scaffold 
remained intact in their spheroid structures within the hydro-
Stimulating Fluid Secretion by Activation of M3 Musca-
rinic Receptors 
To stimulate fluid secretion, salivary acinar-like cells were 
treated with acetylcholine. Addition of 50 µM acetylcholine 
induced a robust calcium response in self-assembling acini- 55 
like structures cultured on 2.5D hydrogels (FIG. 27A). 
Acini-like structures on hydrogels were imaged without 
saline buffer to minimize movement of hydrogels in the 
liquid. The calcium response peak seen at -5 min can be 
attributed to the diffusion time needed by the neurotrans- 60 
mitter to pass through the hydrogel to the cells. Treatment 
with 100 µM acetylcholine produced calcium oscillations 
lasting over 20 min in multiple cells within a self-assembled 
acinus-like structure (FIG. 27B). Oscillations from different 
structures varied in intensity. Single cells that were not 65 
assembled into structures did not respond to the agonist. 
Experiments were performed three times with each agonist 
gel for over 3 weeks (FIG. 28F), survived implantation in 
vivo, and continued to produce a-amylase. 
Discussion 
A biodegradable and human-compatible scaffoldable to 
support growth and differentiation of human salivary gland 
cells into functional salivary units that secrete fluid and 
protein upon stimulation is a key step toward creation of an 
artificial salivary gland. Previously we reported the isolation 
of human salivary acinar cells that self-assemble into acini-
like structures and express salivary biomarkers when cul-
tured on ECM derived human-compatible biomimetic pep-
tides. To better mimic the in vivo environment, we 
developed an HA-based, 2.5D hydrogel culture system that 
can support the growth and partial differentiation of 3D 
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acini-like structures in vitro, but cannot be used to encap-
sulate cells. 6 We now report conversion of our 2.5D model 
28 
to a fully 3D culture system that promotes organized growth 
and differentiation of salivary acinar-like cells into func-
tional acini-like structures and fosters their long-term sur- 5 
viva! in the 3D scaffold in vivo as well as in vitro. It should 
responses by cells within an acinus. It is likely that the 
organized acini-like structures in 3D respond better and 
more consistently because they possess gap junctions indi-
cating cellular connectivity. 
Branching morphogenesis is a key step in the develop-
ment of the salivary gland. Parasympathetic innervation 
occurs early in the developing salivary gland and an inter-
action of the nerves with the salivary gland parenchyma is 
critical for further gland development. It was reported 
be noted that the 3D gels we used to encapsulate the cells are 
softer (G'-68 Pa) than the 2.5D gels (G'-1490 Pa) and they 
contain polyethylene glycol, but they allow full encapsula-
tion of primary cells. 
Groups that reported salivary acini-like structures or 
spheroids growing in 2D or 2.5D obtained less well orga-
nized salivary structures compared to those seen in 3D 
cultures. Our results are consistent with this observation, and 
suggest that dimensionality determines the organized assem-
bly of complex structures as much or more than gel com-
position. Additionally, most of these 3D salivary cultures 
used Matrigel™, collagen I or other animal derived products 
for their scaffolds. The human-compatible 3D culture system 
reported here supports the growth of organized spherical 
structures that merge to form larger acini-like structures with 
a central lumen and can be maintained long-term in vitro. 
These stable spheroid structures expressed essential salivary 
biomarkers and neurotransmitter receptors. The presence of 
10 recently that removal of the parasympathetic ganglion dur-
ing early salivary gland development reduces progenitor cell 
populations, which could be rescued with carbachol, an 
acetylcholine analog (Knox et al., 2010). Thus, treatment 
with muscarinic agonists can aid in branching morphogen-
15 esis and further development of salivary glands. 
A major challenge in the field of tissue engineering is 
necrosis of implants in vivo. To ensure survival of our 
implant in vivo, we performed a series of animal studies 
with our 2.5D and 3D hydrogels. Implantation studies 
20 showed long-term survival and maintenance of spheroid 
structures in 3D but dispersal of cells in 2.5D. We believe 
these cells in 3D can be maintained for a longer time in the 
presence of the protective hydrogel and more normal cell-
cell interactions. 
~ adrenergic and M3 muscarinic receptors on acinar-like 25 
cells in 3D suggested that these cells can activate fluid and 
protein transport upon treatment with neurotransmitters. 
Although the 3D system reported here reflects an impor-
tant advance because it produces protein and fluid upon 
stimulation, it still lacks essential machinery for full salivary 
restoration. Future studies can incorporate ductal and myo-
epithelial cells to form complete functional polarized sali-
Saliva contains an array of protein components that 
provide saliva with its anti-bacterial, anti-viral, anti-fungal, 
lubricative, digestive and buffering qualities. a-Amylase, 
one of the most abundant proteins in saliva, is an essential 
enzyme that breaks down starch and initiates digestion. 
Acini-like structures in both 2.5D and 3D hydrogels 
increased production of a-amylase positive granules upon 
stimulation with norepinephrine and isoproterenol, indicat-
ing a functional protein secretion pathway was present. 
While a robust increase in the secretion of amylase and its 
accumulation in the hydrogel were promising, it also indi-
cated a reverse polarity among many of the structures. 
Staining with MUCl (a marker of polarity) revealed that 
only a few structures had luminal MUCl (not shown). 
Lessons from studies with mammary gland acini suggest 
that cues from the ECM and the encasing myoepithelial cells 
are needed to reverse inside-out acini and attain correct 
polarity, a final step in functional assembly of the salivary 
gland. Co-cultures with salivary myoepithelial cells may 
correct the acini polarity and ensure unidirectional secretion 
into the ductal lumen. 
Fluid secretion is an important function of salivary acini 
where it aids essential oral functions including mastication 
and speech. Several reports showed increases in Ca, upon 
treatment with acetylcholine (or carbachol) in parotid or 
submandibular acini and dissociated cells. Here we demon-
strated the induction of calcium oscillations upon neu-
rotransmitter stimulation of 3D acini-like spheroids in a 
human-compatible hydrogel culture system. The increase in 
Ca, and the recurring oscillations induced by acetylcholine 
among our 2.5D and 3D cultures indicates a functional fluid 
production pathway. Calcium oscillations have been 
reported by carbachol treatment of intact parotid acini, 
indicating that our 3D spheroids resemble glandular acini, 
functionally. Variability in intensity of the calcium response 
among cells in 2.5D reflects the lack of uniform organization 
among the structures in 2.5D. Spheroids in 3D were more 
organized and responded to stimulation better than the 
less-organized structures in 2.5D. Gap junctions among 
salivary acinar cells can induce synchronous calcium 
30 vary units with assembled ductal structures that can modify 
and transport salivary fluid. The studies reported here pro-
vide strong evidence that we can develop a functional, 
neurotransmitter responsive artificial gland that can be 
incorporated into the buccal mucosa or native salivary gland 
35 of patients to restore both fluid and salivary proteins present 
in saliva. 
Therefore, the present disclosure is well adapted to attain 
the ends and advantages mentioned as well as those that are 
inherent therein. The particular embodiments disclosed 
40 above are illustrative only, as the present disclosure may be 
modified and practiced in different but equivalent manners 
apparent to those skilled in the art having the benefit of the 
teachings herein. Furthermore, no limitations are intended to 
the details of construction or design herein shown, other than 
45 as described in the claims below. It is therefore evident that 
the particular illustrative embodiments disclosed above may 
be altered or modified and all such variations are considered 
within the scope and spirit of the present disclosure. While 
compositions and methods are described in terms of "com-
50 prising," "containing," or "including" various components 
or steps, the compositions and methods can also "consist 
essentially of' or "consist of' the various components and 
steps. All numbers and ranges disclosed above may vary by 
some amount. Whenever a numerical range with a lower 
55 limit and an upper limit is disclosed, any number and any 
included range falling within the range is specifically dis-
closed. In particular, every range of values ( of the form, 
"from about a to about b," or, equivalently, "from approxi-
mately a to b," or, equivalently, "from approximately a-b") 
60 disclosed herein is to be understood to set forth every 
number and range encompassed within the broader range of 
values. Also, the terms in the claims have their plain, 
ordinary meaning unless otherwise explicitly and clearly 
defined by the patentee. Moreover, the indefinite articles "a" 
65 or "an," as used in the claims, are defined herein to mean one 
or more than one of the element that it introduces. If there 
is any conflict in the usages of a word or term in this 
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specification and one or more patent or other documents that 
may be incorporated herein by reference, the definitions that 
are consistent with this specification should be adopted. 
What is claimed is: 
1. A hydrogel network comprising: a hyaluronic acid 5 
macromer crosslinked with a crosslinker, wherein the cross-
linker is a multiblock copolymer, wherein the multiblock 
copolymer comprises an alternating copolymer of poly 
( ethylene glycol) (PEG) and a peptide epitope of perlecan, 
or an alternating copolymer of poly(acrylic acid) and a 10 
hydrophobic peptide. 
2. The hydrogel network of claim 1, wherein the multi-
block copolymer comprises a multiblock copolymer of 
perlecan domain IV (PlnDIV) peptide alternating with PEG. 
30 
12. The method of claim 11, wherein the multiblock 
copolymer comprises a multiblock copolymer of PlnDIV 
peptide alternating with PEG. 
13. The method of claim 11, wherein the multiblock 
copolymer comprises a multiblock copolymer of poly 
(acrylic acid) alternating with a hydrophobic peptide of 
sequence (VPGVG)2. 
14. The method of claim 11 further comprising encapsu-
lating cells within the hydrogel network. 
15. The method of claim 11 further comprising encapsu-
lating hyaluronic acid hydro gel particles within the hydrogel 
network. 
16. The method of claim 11 wherein two or more hydrogel 
networks are combined to form a secondary hydrogel net-
work. 
17. The method of claim 16 wherein the secondary 
hydrogel network is a 3D construct. 
3. The hydrogel network of claim 1, wherein the multi- 15 
block copolymer comprises a multiblock copolymer of 
poly(acrylic acid) alternating with a hydrophobic peptide of 
sequence (VPGVG)2 . 
4. The hydrogel network of claim 1 wherein the hydrogel 
network is biocompatible. 
18. A method of constructing a biomimetic matrix com-
20 prising: 
providing a hyaluronic acid hydrogel network comprising 
a hyaluronic acid macromer crosslinked with a cross-
linker, wherein the crosslinker is a multiblock copoly-
mer comprising an alternating copolymer of poly( eth-
5. A kit comprising a hyaluronic acid macromer and a 
crosslinker, wherein the crosslinker is a multiblock copoly-
mer, wherein the multiblock copolymer comprises an alter-
na!ing copolymer of poly(ethylene glycol) and a peptide 
ep1top_e of_ perlecan, or an alternating copolymer of poly 25 
(acrylic acid) and a hydrophobic peptide. 
6. The kit of claim 5 wherein the hyaluronic acid mac-
romer comprises an unsaturated double bond. 
7. The kit of claim 5 wherein the hyaluronic acid mac-
romer comprises an acrylate. 
8. The kit of claim 5 further comprising hyaluronic acid 
hydrogel particles. 
9. The kit of claim 8 wherein the hyaluronic acid hydro gel 
particles further comprise a growth factor. 
30 
10. The kit of claim 8 wherein the hyaluronic acid 35 
hydrogel particles are angiogenic. 
11. A method of forming a hydro gel network comprising: 
providing a hyaluronic acid macromer; providing a cross-
linker, wherein the crosslinker is a multiblock copolymer 
co~prising an alternating copolymer of PEG and a peptide 40 
ep1top_e of_ perlecan, or an alternating copolymer of poly 
(acrylic acid) and a hydrophobic peptide, and crosslinking 
the hyaluronic acid macromer with the crosslinker to form 
the hydrogel network. 
ylene glycol) (PEG) and a peptide epitope of perlecan, 
or an alternating copolymer of poly(acrylic acid) and a 
hydrophobic peptide; 
providing hyaluronic acid hydrogel particles; 
providing salivary cells; and 
co-encapsulating the hyaluronic acid hydrogel particles 
and the salivary cells within the hyaluronic acid hydro-
gel network to form cell-laden microgel modules. 
. 19. T~e method of claim 18, further comprising: combin-
mg mult1_ple ~ell-laden microgel modules into a secondary 
hyaluromc acid network to yield a 3D network. 
20. The method of claim 18 wherein the cells are treated 
with at least one of a ~-adrenergic agonist, a M3 muscarinic 
agonist, and combinations thereof. 
21. A composition comprising: a hyaluronic acid mac-
romer;_ ~ crosslinker comprising a multiblock copolymer 
compnsmg a copolymer of PlnDIV peptide alternating with 
PEG; and hyaluronic acid hydrogel particles. 
22. The composition of claim 21 further comprising cells. 
* * * * * 
